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A brief summary of the work to be incorporated in the thesis entitled
“STUDIES ON SYNTHETIC DRUGS’’  has been summarized as under.
    ( A )   STUDIES ON  PYRIMIDINE   DERIVATIVES
    ( B )   STUDIES ON PYRIMIDO[4,5-d]PYRIMIDINES
    ( C )   STUDIES ON 1,4-DIHYDROPYRIDINE
    ( A )   STUDIES ON  PYRIMIDINE   DERIVATIVES
             Pyrimidines  represents one of the most active classes of compounds
possessing a wide spectrum of biological activities viz. significant in vitro activity
against unrelated DNA and RNA viruses including  Polio and  Herpes viruses,
diuretics, antitubercular, antihypertensive etc. Some pyrimidines which occur
as natural products like nucleic acids  and vitamin-B and can be used as
therapeutic agent for the treatment of AIDS and antitumor . Keeping in association
of pyrimidines with varied activities, it was thought worthwhile to synthesize some
newer pyrimidines  and its derivatives, which can be summarized as under.
PART - I :        STUDIES ON PYRIMIDINES
SECTION - I:   Preparation and biological evaluation of 2-Mercapto-4-amino-5-
                       cyano-6-(1’-N-phenyl-3’-arylpyrazol-4’-yl)-1,6-dihydro pyrimidines.








The pyrimidines (I) have been prepared by the cyclocondensation of different 3-
aryl-1-N-phenyl-1H-pyrazole-4-carboxaldehyde, thiourea and malononitrile.
SECTION - II : Preparation and biological evaluation of 2-Hydroxy-4-amino- 5-
                          cyano-6-(1’-N-phenyl-3’-aryl pyrazol-4’-yl )-1,6-dihydro-pyrimidines.
                                                                         (II)                                          R=Aryl
The pyrimidines (II) have been prepared by the cyclocondensation of different
3-aryl-1-N-phenyl-1H pyrazole-4-carboxaldehyde, urea, and malononitrile.
SECTION - III : Preparation and biological evaluation of 2,4-Diamino-5-cyano-6-
                           (1’-N-phenyl-3’-aryl pyrazol-4’-yl )-1,6-dihydro pyrimidines.
     (III)                                               R=Aryl
The pyrimidines (III) have been prepared by the cyclocondensation of different 3-















SECTION - IV :  Preparation and  biological  evaluation  of  2-Mercapto-methyl-4-
                             amino-5-cyano-6-(1’-N-phenyl-3’-aryl-pyrazol- 4’-yl )-1,6-dihydro-
                             pyrimidines.
                                                                        (IV)                                       R=Aryl
The 2-mercapto methyl pyrimidines (IV) have been prepared by the reaction of
2-mercapto-4-amino-5-cyano-6-(1’-N-phenyl-3’-aryl pyrazol-4’-yl)-1,6-dihydro-
pyrimidines with dimethyl sulphate in presence of the base.
SECTION - V :  Preparation and biological evaluation of 2-Methyl sulphonyl-4-
                            amino-5-cyano-6-(1’-N-phenyl-3’-aryl-pyrazol-4’-yl )-pyrimidines.
                                                                       (V)                                        R=Aryl
The 2-methyl sulphonyl-4-amino-5-cyano-6-(1’-N-phenyl-3’-aryl pyrazol-
4’-yl )- pyrimidines (V) have been prepared by the reaction of 2-mercapto methyl-



















SECTION - VI :  Preparation and biological evaluation of 2-[( 2",4"-Dinitro phenyl)
                             -thio]-4-amino-5-cyano-6-(1’-N-phenyl-3’-aryl pyrazol-4’-yl )-1,6-
                              dihydro pyrimidines.
 (VI) R=Aryl
              The pyrimidines (VI) have been prepared by the condensation of 2-mercapto-4-
amino-5-cyano-6-(1’-N-phenyl-3’-aryl pyrazol-4’-yl )-1,6-dihydro pyrimidines with 2,4-
dinitro chloro benzene in the presence of base.
SECTION - VII :  Preparation and biological evaluation of 2-[( 2",4"-Dinitro-
                              phenyl)-sulphonyl]-4-amino-5-cyano-6-(1’-N-phenyl-3’-aryl pyra-
                              zol-4’-yl ) pyrimidines.




















              The pyrimidines (VII) have been prepared by the oxidation of 2-[(2",4"-
dinitrophenyl)-thio]-4-amino-5-cyano-6-(1’-N-phenyl-3’-aryl-pyrazol- 4’-yl )-1,6-
dihydro pyrimidines with hydrogen peroxide.
SECTION-VIII:  Preparation and biological evaluation of 2-[(2’,4’- Dinitrophenyl)-
                             sulphonyl]-4-amino-5-cyano-6-aryl pyrimidines.
                                                                       (VIII)                                                 R=Aryl
          The pyrimidines (VIII) have been prepared by the reaction of 2-[(2’,4’-Dinitro-
phenyl)-thio]-4-amino-5-cyano-6-aryl-1,6-dihydro pyrimidines with  hydrogen peroxide.
PART - II : STUDIES ON 5-CARBOXAMIDO PYRIMIDINES
The growing potent literature of recent years demonstrates that the carboxamido
pyrimidines are used as better cardiovascular, antihypertensive, antitumor,
anticonvulsant agents. Prompted by above facts, some newer carboxamido
pyrimidines have been synthesized as under.
SECTION - I :  Preparation and biological evaluation of 2-Mercapto-4-amino-5-
                          carboxamido-6-(1’-N-phenyl-3’-aryl pyrazol 4’-yl )-pyrimidines.




















 The 2-mercapto-4-amino-5-carboxamido-6-(1’-N-phenyl-3’-aryl pyra- zol-4’-
yl )-pyrimidines (IX) have been prepared by the reaction of  2-mercapto-4-amino-5-
cyano-6-1’-N-phenyl-3’-aryl pyrazol-4’-yl)-1,6-dihydro pyrimidines with
concentrated sulfuric acid at 0 0C.
SECTION - II :  Preparation and biological evaluation of 2-[( 2’,4’- Dinitrophenyl)-
                            Sulphonyl]-4-amino-5-carboxamido-6-aryl pyrimidines.
                                                                  (X)                                         R=Aryl
 pyrimidines (X) have been prepared by the reaction of 2-[(2’,4’-Dinitro
phenyl)-thio]-4-amino-5-carboxamido-6-aryl pyrimidines with hydrogen peroxide.
SECTION - III :   Preparation and biological evaluation of 2-Mercapto 4-amino-5-
                               carboxamido-6-(1’-N-phenyl-3’-aryl-pyrazol-4’-yl )-1,6-dihydro-
      pyrimidines.
                                                                           (XI)                                           R=Aryl
 The pyrimidines (XI) have been prepared by the condensation of different 3-(1’-
N-phenyl-3’-aryl pyrazol-4’-yl)-2-cyano acryl amides with thiourea.
SECTION - IV : Preparation and biological evaluation of 2-Hydroxy 4-amino-5-
                            carboxamido-6-(1’-N-phenyl-3’-aryl-pyrazol-4’-yl)-1,6-dihydro-





















  (XII)                                      R=Aryl
 The pyrimidines (XII) have been prepared by the condensation of different 3-
(1’-N-phenyl-3’-aryl pyrazol-4’-yl)-2-cyano acryl amides with urea.
PART - III : STUDIES ON 4-PYRIMIDINYL SULPHONAMIDES
   The study of sulphonamides has valuable drugs for the diseases like cancer,
tuberculosis, diabetics, malaria, leprosy and epilepsy. These valid observations
lead us to synthesize some novel sulphonamides that have been described as under.
SECTION - I :  Preparation  and  biological  evaluation of  2-Hydroxy-4-(p-aceta-
                           mido phenyl sulphonylamino)-5-carboxamido-6-aryl-pyrimidines.
                                                                           (XIII)                                      R=Aryl
4-pyrimidyl sulphonamides (XIII) have been prepared by the condensation of 2-
hydroxy-4-amino-5-carboxamido-6-aryl pyrimidines with p-acetamido phenyl
sulphonyl chloride in presence of pyridine.
SECTION - II :  Preparation and biological evaluation of 2-Hydroxy-4-(p-amino




















                                                                    (XIV)   R=Aryl
The 2-hydroxy-4-(p-amino phenyl sulphonyl amino)-5-carboxamido-6-aryl
pyrimidines (XIV) have been prepared by the hydrolysis of 2-hydroxy-4-(p-acetamido
phenyl- sulphonylamino)-5-carboxamido-6-aryl pyrimidines with hydrochloric acid.
 ( B )   STUDIES ON PYRIMIDO[4,5-d]PYRIMIDINES
Pyrimido [4,5-d] pyrimidines have been found to be potent drugs in pharmaceuticals
and possessing a wide range of biological activities viz. antibacterial, antihypertensive,
antitumor, antitubercular activities. In view of these facts, it was contemplated to
synthesize some new pyrimido [4,5-d] pyrimidines, which have been described as
under.
PART -  IV :  STUDIES ON PYRIMIDO[4,5-d]PYRIMIDINES
SECTION - I :  Preparation and biological evaluation of 2-Aryl-5-phenyl-7-merca-
                       pto-4-one-1,2,3-trihydro pyrimido[4,5-d]pyrimidines.
           (XV) R=Aryl
The pyrimido[4,5-d]pyrimidines (XV) have been prepared by the cyclocondensation


















SECTION - II : Preparation and biological evaluation of 2-Aryl-2-methyl-5- phenyl-
                      7-mercapto-4-one-1,2,3-trihydro pyrimido[4,5-d] pyrimidines.
                                                                        (XVI)                R=Aryl
The pyrimido[4,5-d]pyrimidines (XVI) have been prepared by the
cyclocondensation of 2-mercapto-4-amino-5-carboxamido-6-phenyl pyrimidines with
different aromatic acetophenones.
( C )   STUDIES ON 1,4-DIHYDRO PYRIDINES
Dihydro pyridines possess anti hypertensive, cardiovascular, vasodilator ,
antitubercular and anti microbial activities. These valid observations lead us to
synthesize some novel 1,4-dihydro pyridines that have been described as under.
PART- V : STUDIES ON 1,4-DIHYDRO PYRIDINES
 SECTION - I :  Preparation and biological evaluation of 2,6-Dimethyl-4-(1’-N-
                        phenyl-3’-(p-methyl phenyl-pyrazol-4’-yl)-3,5-dicarbethoxy-
                        1,4-dihydro pyridines.

















             The 1,4-dihydro pyridines (XVII) have been prepared by the cyclocondensation
of 1-N-phenyl-3-(4-methyl phenyl)-4-formyl pyrazole, ethyl acetoacetate and
different aromatic amines.
SECTION - II : Preparation and biological evaluation of 1-N-Aryl-2,6-Di-methyl- 4-
                           (1’-N-phenyl-3’-(p-methyl phenyl pyrazol-4’-yl)-3,5-dicarbmethoxy-
                           1,4-dihydro pyridines.
     (XVIII)   R= Aryl
             The 1,4-dihydro pyridines (XVIII) have been prepared by the cyclocondensation
of 1-N-phenyl-3-(4-methyl phenyl)-4-formyl pyrazole, methyl acetoacetate and
different aromatic amines.
SECTION - III :  Preparation and biological evaluation of 1-N-Aryl-2,6-Dimethyl-4-
                             (1’-N-phenyl-3’-(p-bromo phenyl pyrazol-4’-yl)-3,5-dicarbethoxy-
                             1,4-dihydro pyridines.
















The 1,4-dihydro pyridines (XIX) have been prepared by the cyclocondensation
of 1-N-phenyl-3-(4-bromo phenyl)-4-formyl pyrazole, ethyl acetoacetate and different
aromatic amines..
 SECTION - IV : Preparation and biological evaluation of 1-N-Aryl 2,6-Dimethyl-4-
                            (1’-N-phenyl-3’-(p-bromo phenyl pyrazol-4’-yl)-3,5-dicarbmethoxy-
                            1,4-dihydro pyridines.
        (XX)   R= Aryl
The 1,4-dihydro pyridines (XX) have been prepared by the cyclocondensation
of 1-N-phenyl-3-(4-bromo phenyl)-4-formyl pyrazole, methyl acetoacetate and
different aromatic amines.
The compounds have been screened for their in vitro therapeutic assay
like antibacterial activities towards S. pyogens MTCC-442 and S. aureus
MTCC-96 (Gram positive) and E.coli MTCC-443 and B.subtilis MTCC-441
(Gram negative) bacterial strain and antifungal activity towards Aspergillus
niger MTCC-282 and Candida albicans  MTCC-227 at different concentrations
(Minimum Inhibitory  Concentration) . The biological activities of synthesized
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STUDIES ON SYNTHETIC DRUGS
(A) Drug
The word drug is derived from the French word “drogue” which means
‘a dry herb’. It is the single active chemical entity present in a medicine that is
used for diagnosis, prevention, treatment / cure of a disease. This disease
oriented definition of drug does not include contraceptives or use of drugs for
improvement of health. According to “WHO” a drug may be defined as “Any
substance or product which is used or intended to be used for modifying or
exploring physiological system as pathological status for the benefit of the
recipient”.
(B) Pharmacology
Pharmacology is the science of drugs. In a broad sense, it deals with
interaction of exogenously administered chemical molecules (drugs) with living
system. It encompasses all aspects of knowledge about drugs, but most
importantly those that are relevant to effective and safe use for medicinal
purposes. For thousands of years most drugs were crude natural products of
unknown composition and limited efficiency. Only the over effects of these
substances on the body were rather imprecisely known, but how the same were
produced was entirely unknown. Over the past 100 years or so, drugs have been
purified, chemically characterized and a vast variety of highly potent and
select ive new drugs has been developed. The two main div is ions of
pharmacology are pharmacodynamics and pharmacokinetics.
(a) Pharmacodynamics :  It is derived from the Greek word “dynamic” means
power. What the drugs does to the body ? This includes physiological and bio-
chemical effects of drugs and their mechanism of action at macro molecu-
lar / sub cellular organ systems.
(b) Pharmacokinetics :  It is derived from the Greek word ‘Kinesis’ means
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movement. What the body does to the drug ? This refers to movements of
the drug in and alternation of the drug by the body; includes absorption,
distr ibut ion, binding /  local izat ion /  storage, biotransformation and
excretion of the drug.
Some other important aspects of pharmacology are given as under :
* Pharmacotherapeut ics  :  I t  i s  the  app l i ca t ion  o f  pharmaco-
dynamic  information together with knowledge of the disease for its
prevention, mitigation or cure.
* Clinical  Pharmacology  :  I t  is  the scient i f ic  study of  drug in man.
It  inc ludes pharmacodynamic and pharmacokinet ic  invest igat ion
i n healthy volunteers and in patients; evaluation of efficiency and safety
o f  d rugs  and  compara t i ve  t r ia l s  w i th  o ther  fo rms o f  t rea tments ;
surveillance of patterns of drug uses, adverse effects, etc.
* Chemotherapy : It is the treatment of systemic infection / malignancy
with speci f ic  drugs that  have select ive toxic i ty  for  the infect ing
organism / malignant cell with less effect on the host cells.
Drugs in general, can thus be divided into :
* Pharmacodynamic agents : These are chemical substances designed
to have pharmacodynamic effect in the recipient.
* Chemotherapeut ic  agents :  These are chemical substances de-
signed for the treatment of infectious diseases or by the proliferation of malig-
nant cells.
(c) Essential Drug Concept: The ‘WHO’ has defined Essential Drugs as
“those that satisfy the healthcare needs of majority of the population; they should
therefore be available at all times in adequate amounts and in appropriate
dosage form”.
It has been realized that only a handful of drugs out of the multitude
G e n e r a l  I n t r o d u c t i o n 14
available can meet the health needs of majority of the people in any country, and
that may be well tested and cheaper drugs are equally (or more) efficient and
safe as their newer more expensive congeners. For optimum utilization of
resources, governments (specially in developing countries) should concentrate
on these drugs by identifying them as Essential Drugs. The “WHO” has laid down
criteria guide selection of an essential drug :
(I) Adequate data on its efficiency and safety should be available from
          clinical studies.
(II) It should be available in a form in which quality, including bioavailability,
and stability on storage can be assured.
(III) Its choice should depend upon pattern of prevalent diseases; availability
o f  fac i l i t ies  and t ra ined personnel ;  f inanc ia l  resources;  genet ic ,
demographic and environmental factors.
(IV) In case of two or more similar drugs, choice should be made on the basis
          of their relative efficiency, safety, quality, price, availability and cost
          benefit ratio should be a major consideration.
(V) Choice may also be influenced by comparative pharmacokinetic properties
and local facilities for manufacture and storage.
(VI) Most essential drug should be single compound. Fixed ratio combination
products should be included only when dosage of each ingredient meets
the requirements of a defined population group, and when the combination
has a proven advantage.
(VII) Selection of essential drug should be a continuous process which should
take into account the changing priorities for public health action, epide-
miological condition as well as availability of better drugs/ formulations and
progress in pharmacological knowledge.
(C)  Drug Development
Many natural products by trial and error, came into practise for combating
human ailments existent during early human observation. With the advent of
modern scientific approach, various plant medicines came under chemical
scrutiny, ultimately leading to the isolation of active principles since early.
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Such compounds either in extract form or in pure form became a part of
pharmacopoeias. For instance, though the Chinese drug, Mauhang was in use
for over 5000 years for the treatment of various types of fever and respiratory
ailments, its active principle, Ephidrine was isolated in 1887. In 1925 chemical
investigations followed by pharmacological evaluation led this compound into the
modern medicine. Similarly during this period, urea stibamine was introduced as
the first drug in 1920 for the treatment of Kala-azar. In 1930, De Rauwolfia
preparation were first employed for sedative and hypotensive properties.
A drug is a substance having abnormal effect on certain body functions eg.
Strychnine stimulates the action of heart and aspirin retards its action. Since both
of them effects abnormally, the two substances are known as drugs. Chemical
sciences contributed extensively new discoveries leading to useful drugs since
after 1930. The modern concept of drug discovery started in 1933 by Gerhand
Domagk with his finding of “Prontosil Red” , a compound responsible for the
antibacterial activity. The advent of sulphonamides  drew the attention for the
different activities of various chemicals for bacterial and human cells, this impor-
tant factor prompted Florey and Chain in 1939 to investigate penicillin  which
was discovered ten years earlier by Alexander Fleming. The spectacular
chemotherapeut ical  propert ies of  penic i l l in and i ts dramatic war-t ime
development for the treatment of wounds made penicillin , a most commonly used
inexpensive drug.
           A large number of important drugs have been introduced during the period
of 1940 to 1980. This period is known as “Golden period” of new drug discovery.
Thus starting from 1933 - the first antibacterial drug prontosil  leading to various
sulpha drugs ; 1940 – penicillin  ; 1945 – chloroquine  – antimalarial ; 1950 –
Methyldopa  – anti-hypertensive;  1967 – chlorothiazine -diuretic ; 1958 - adr-
energic beta blockers coronary vasodilatory; 1960 - semi synthetic penicillin  -
ant ibacter ial ;  1965 - tr imethoprim -antimicrobial ;1967-  d isodium
chromoglycoate - antiallergic; 1972 - cimetidine H2 – antagonist; 1975
-verapamil- calciumantagonist and 1981 - captopril  - antihypertensive. There
are some specific examples representing new therapeuticagent  eg. Metormine glipizide-
anti diabetic.
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(D) Latest Drug Developments
The current interest in the creation of large, searchable libraries of
organic compounds has captured the imagination of organic chemists and the
drug discovery community. In numerous laboratories the Efforts are focused on
the introduction of chemical diversity, which have been recently reviewed and
pharmacologically interesting compounds have been identified from libraries of
widely different compositions.
Today, the chief source of agents for the cure, the mitigation or the
prevention of diseases are the organic compounds, natural or synthetic, together
with so-called organometallics. Such agents have their origin in a number of ways
(a) from naturally occurring materials - of both plant and animal origin, and (b)
from the isolation of organic compounds synthesized in laboratory whose struc-
tures are closely related to those of naturally occurring compounds for eg. atro-
pine, steroids, morphine, cocaine etc. that have been known to possess useful
medicinal properties.
The process of drug design is extensively driven by the instinct  and expe-
rience of pharmaceutical research scientists. It is often instructive to attempt to
“capture” these experiences by analyzing the historical record that are successful
drug design projects of the past. From this analysis, the inferences are drawn
which play an important role in shaping our  current and future projects. Towards
this region, we would like to analyse the structures of a large number of drugs -
the ultimate product of a successful drug design effort. Our goal for this is to  begin
to deconvolute this information in order to apply it to design of new drugs.
Different kinds of drugs are developed for different types of diseases viz.
which can be defined with their names of the modern drugs are as under.
(a) Anticancer drugs
The drugs, which stops the abnormal growth of cell tissues in human body,
are termed as anticancer drug. Vinblastin  and Busulphan are the novel
anticancer drugs.
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(b) Hepatoprotective drugs
Drugs, which gives vitality to liver and protects liver by giving immunity power
against antibodies, are termed as Hepatoprotective drug.
(c) Antimalarial drugs
Drugs, which kills the plasmodium causing malaria are called antimalarial
drug. Combination of Sulphamethoxazole  with Pyrimethamine is a novel
antimalarial drug.
(d)      Drug for meningitis
Drugs, which cures the inflammation of meningitis, are termed as
meningitis drugs Cifalexin  is a novel meningitis drug.
(e)      Drug for typhoid
Drugs, which kills the bacteria of Salmonella typhi causing typhoid are
known as typhoid drugs. A novel drug for typhoid is Ciprofloxacin .
(f)       Antidiabetic drugs
Drugs, which converts the excess glucose of blood into glycogen are termed
as antidiabetic drugs. Novel antidiabetic drugs are Metformin, Glipizide  and
Gliclazide.
(g) Antitubercular drugs
Drugs, which kills the bacteria of mycobacterium tuberculosis and thus cures
lesions of pleural cavity. A novel antitubercular drug is Ethambutol.
(h) Antiasthamatic drugs
             Drugs, which prevents the attack of asthama and gives relax respiration
are called antiasthamatic drugs. Novel antiasthamatic drugs are Ethophylline,
Theophylline and Asmon.
(i) Antihypertensive drugs
            Drugs, which normalizes the blood pressure by dilating blood vessels are
called antihypertensive drugs. Novel antihypertensive drugs are Atenolol,
Amlodipine  and Nifedipine.
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(j)        Anti-AIDS drugs
          Drugs, which kills the viruses of AIDS i.e., HIV-1 and HIV-2 are called
anti-AIDS drugs. Novel drugs are Zidovudine, Acyclovir  and Didanosine .
(k) Antacid drugs
           Drugs, which neutralize the acid in stomach and stops excessive
secretion of acid, are called antacid drugs. Novel antacid drugs are Omeprazole
and Lansoprazole.
(l)      Non steroidal antiinflammatory drugs (NSAID)
Drugs, which gives relief from fever, pain and inflammation are called
NSAID. Novel NSAID are Pyroxicam , Meloxicam  and Nimesulide.
Different kind of drugs generally used are designed as anaesthetic,
anti tuberculostat ic, antihypertensive, anticonvulsant, anthelmintic,
antiinflammatory, sedative and hypnotics which prompted us to synthesise drugs
having pyrimidine,  pyrImido[4,5-d]pyrimidine, 1,4-dihydro pyridine  moieties
as a better therapeutic activity.
Aims and objectives of the present investigation are
(a) To generate several biologically active moieties such as pyrimidines,
          pyr imido[4 ,5-d] pyrimidines, and1,4-dihydropyridines.
(b) To characterize these products for their structural assignment using various
             spectroscopic techniques like IR, PMR and Mass spectroscopy.
(c) To screen these new derivatives for their antimicrobial activity using different
strains of bacteria and fungi and to compare antimicrobial activity with
different known drugs at different concentrations for their MIC values.
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In view of these facts, the research work presented in thesis are as
follows.
    ( A )   STUDIES ON  PYRIMIDINE   DERIVATIVES
    ( B )   STUDIES ON PYRIMIDO[4,5-d]PYRIMIDINES
    ( C )   STUDIES ON 1,4-DIHYDROPYRIDINE
P A R T - I
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Pyrimidine  (1) is a six membered heterocyclic compound consisting of
two nitrogen atoms at 1 and 3 positions of heterocyclic ring.
Generally pyrimidine derivatives such as 2-hydroxy-substituted-pyrimidine,
2-mercapto-substituted-pyrimidine  and 2-amino-substituted-pyrimidine  are
studied. Pyrimidines  have been isolated from the nucleic acid hydrolysates.
Pyrimidines  are among those molecules that make life possible, have
been some of the building blocks of DNA and RNA. Several analogues of
pyrimidines  have been used as compounds that interfere with the synthesis and
functioning of nucleic acids e.g. fluorouracil, which has been used in cancer
treatment. Also there are some thiouracil  derivatives, which produce adverse
reduction in susceptible patients and found more potent and less likely to
produce side effects and is being widely used1. There are several other
important groups of pyrimidines  with medicinal uses.
Pyrimidine  ring carrying various substituents may be built up from two or
three aliphatic fragments by the principle synthesis or by a variety of other
syntheses, which are complimentary rather than alternative to it. An alternative
method of synthesis is the isomerisation or break down of another heterocycles
such as hydration of purine , but such methods are rarely used. Pyrimidine  is
best  considered as a resonance hybrid to which the uncharged equivalent Kekule
N
N
   pyrimidine
(1)
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structures 2 and 2a and charged structures 2b and 2g contributes. The self con-
sistent p (pi) electron densities required for the ground state of pyrimidine are
0.776, 0.825 and 1.103 for positions 2, 4  and 5 respectively2. Despite considerable
localization of p (pi) electrons at nitrogen atoms of pyrimidines  the ring system
is still sufficiently aromatic to possess substantial stability. This has a great
advantage in the primary synthesis of pyrimidines .
The first primary synthesis from aliphatic fragments was carried out by
Frankland et al. in 1848. Since then a many distinct primary synthetic methods
have been devised3-12.  It is also possible to prepare pyrimidines  from other
heterocyclic compounds such as pyrrole13 , imidazole 14 , isoxazole and
oxazole15,16, pyridine 17, pyrazine 18, 1,3,5-triazine19, oxazine20, thiazine 21 by
different processes.
SYNTHETIC METHODS FOR PYRIMIDINES
Various methods for synthesis of pyrimidines   which are reported in the
literature are as follows.
(a) By the condensation of urea and malonic acid led to formation of pyrimidine22.
(b) By the condensation of malonic ester and urea led to formation of pyrimidine23
(c) By the condensation of formamidine with phenylazomalononitrile led
to formation of 4,5,6-triamino pyrimidine24.
(d) By the condensation of aromatic aldehydes, ß-ketoester  or substituted
ß- ketoester with urea or thiourea led to formation of pyrimidines25.
(e) By the condensation of thiourea  and substituted ß-ketoester  in presence
of sodium ethoxide  led to formation of 2-mercapto pyrimidines26
(f) By the condensation of chalcones with dicyandiamide  in presence of
























(g) By thermal or microwave irridiation of thiourea and substituted b-keto ester
in presence of dimethylformamide  led to formation of substituted tetra
hydro pyrimidines.28
(h) One pot synthesis of substituted dihydropyrimidin-2-ones catalysed
by CuCl2.
29
(i) Synthesis of 3,4-dihydropyrimidin-2-(1H)-ones/thiones  under microwave
irradiation.30
(j) One pot efficient and novel synthesis of dihydropyrimidin-2-(1H)-ones
catalysed by Tin (II) chloride (SnCl2)
.31
(k) By microwave induced eco-friendly solvent free Biginelli reaction catalysed
by calcium chloride.32
Pyrimidines have found their applications as herbicidal33and pesti-
cidal34,35  agents. Yoshida et al.,36 have synthesized 4-amino-5-formyl-2-
mercapto pyrimidines  as agrochemical intermediates.  Srivastava C. et al.,37
have synthesized new substituted pyrimidines  (3) as  potential insecticides. N.
Yasushi et al.,38  synthesized 6-(1-fluoro ethyl)-5-iodo-4-alkylamino pyrimidines
(4) as pesticides for agriculture and horticulture. Besides such a great biological
importance of pyrimidines , they also contribute to an important class of dye viz.
trichloro pyrimidine39  dye which is a reactive dye. Pyrimidines also have
applications in liquid crystal composition.40 Many synthetic members of pyrimidines
are important as vulcanizing accelerator agents and  photography stabilizer. 41
PHARMACOLOGICAL IMPORTANCE OF PYRIMIDINES
Numerous pyrimidines  are well known drugs for variety of diseases. They
may be placed in four categories viz. barbiturates, sulfonamides, antimicrobials


















chroticacid, willardiline, tetradotoxine, becimethrian (5), blasticidine (6),
cougerotin, amicetin, bamicetin  and plicacetin, phleomicine, blemycin  and
related families (7).
Pyrimidine  derivatives have wide varieties of usages. Pyrimidine  ring
system is also present in Vitamin B2 and folic acid. Pyrimidine  ring system
having a mercapto group occupy a unique position in medicinal chemistry. 42
These types of derivatives play a vital role in biological processes43-45 as well
as synthetic drugs.46
Some of the therapeutic activit ies of pyrimidine derivatives can be
summarized as follows.
(a) Antithyroid47,48 (b)      Antitumor49-51
(c)      Antihypertensive 52-54               (d)      Antiinflammatory55-57
(e)      Diuretic58 (f)       Antimalarial59-61
(g)      Antispasmodic62 (h)      Anticonvulsant63
(i)       Antineoplastic64,65 (j)       Anthelmintic66
(k)      Antimicrobial67-92 (l)       Cardiovascular93-95
(m)     Antiviral96-99 (n)      Platelet aggregation inhibitor100,101



























The basis of any rational drug discovery programme is fundamently, the
Medicinal Chemistry. Although the synthesis of modified nucleic acids  has been
a subject of interest for some time, the intense focus on the medicinal chemistry
of oligonucleotides dates perhaps to not more than five years. As a result of this,
the scope of medicinal chemistry has recently been expanded enormously, but
the biological data of supporting the conclusions about synthetic strategies have
just begun to emerge.
Modi f icat ions in the base,  sugar and phosphate moei t ies of
oligonucleotides and oligonucleotide conjugates have been reported. The
subjects of medicinal chemical programmes include approaches to create
enhanced affinity and more selective  affinity for RNA  or duplex structures, the
ability to cleave nucleic acid targets, enhanced nuclease stability, cellular
uptake and distribution, in vivo  tissue distribution, metabolism and clearance.
Although substantial progress in the medicinal chemistry of oligonucleotides has
been made in the past three years, it is not yet possible to reach the conclusion
about the therapeutic ability of the novel modifications. Preliminary data on
effects on nuclease stability and hybridization properties for a few modifications
and activity in vitro suggest that the next generation of oligonucleotides may
display substantially improved potencies and selectivity.
PYRIMIDINE MODIFICATIONS (Nucleotide)
A relatively large number of modified pyrimidines  have been synthesized
and now incorporated into oligonucleotides and evaluated. The principle sites of
modification are   C-2, C-4, C-5 and C-6. (8). These and other nucleoside














Sites of pyrimidine Modification
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In as much as the C2 position is involved in Watson-Crick hybridization,
oligonucleotides containing C2 alkyl modified pyrimidines have shown unattractive
hybridization characters. However, an oligonucleotide containing 2-thio
thymidine(9) was found to hybridize well to DNA  and, in fact even better to RNA
with a thermal melting temperature ( DTm) value of 1.5 °C/modification. In a differ-
ent study, oligoribonucleotides with 2’-O-methyl-2-thiouridine(10) exhibited a
thermal melting temperature ( DTm) value of +5.5°C/modification when hybridized
against RNA  resulting from a highlly preoganized RNA -like C3’-endo conforma-
tion (attributed to the combination of 2-thio modification and 2’-O-Me substitu-
ent). Oligonucleotides with this modification also exhibit better hybridization dis-
crimination for the wobble uracil-guanosine  (U-G) base pair formation compared
to the normal uracil-adenine (U-A) base pair. This selectivity is a result of weaker
hydrogen bonding and increased steric bulk of the 2-thiocarbonyl group.108
In contrast, the pyrimidine modifications in 4-position with interesting
properties have been reported. 4-Thiopyrimidines(11,12) have been incorporated
into oligonucleotides with no significant negative effect on hybridization.
However, recent studies have shown destabilization in the normal uracil-adenine
(U-A) base pair formation and stabilization of the wobble uracil-guanosine
(U-G)  base pair for 4-thiouridine. A bicyclic and an 4-methoxy analog of
cytosine were shown to hybridize with both purine bases in DNA  with thermal
melting temperature (Tm) values approximately equal to that of natural base pairs.
Additionally, a fluorescent base has been incorporated into oligonucleotides and



















The pyrimidine modification at C 5 position including halogenated nucleo-
sides have been reported. Although the stability of duplexes may be enhanced by
incorporation 5-halogenated uracil containing nucleosides, the occasional
mispairing with guanidine and the potential that the oligonucleotide might
degrade and release toxic nucleosides analogs cause concern. Oligonucleotides
containing 5-propynylpyrimidine(14,15) modification have been shown to
enhance the duplex stability thermal melting temperature (DTm = 1.6°C/modifi-
cation ), and support RNase H activity. The 5-heteroaryl-pyrimidines  were also
shown to  increase the stability of duplexes . A more dramatic influence was
reported for the tricyclic 2’-deoxycytidine analoges, termed phenoxazine,
exhibiting an enhancement of 2-5°C/modification, depending on the positioning of
the modified bases.110
As expected, modifications in the C6 position of pyrimidines  are highly
dupled destabilizing. Oligonucleotides containing 6-azapyrimidines(16) have
been shown not only to reduce the  thermal melting temperature (Tm) value by
1-2°C per modification, but also to enhance the nuclease stability of oligonucle-











































The increasing interest in the early 1970s in properties and use of interferon
(IFN) together with the difficulty in producing useful amounts of interferon (IFN)
led to the search for agents that would induce IFN in the host. Precedenced at
that time for interferon (IFN) inducers included viruses and bacterial wall constituents
and entities of large molecular weight such as the polynucleotides. There were
also several examples of low molecular weight substances such as certain antibiotics
and the antiviral agent, tilorone.112-113 In 1976 it was reported that 6-methyl
pyrimidinone (2-amino-5-bromo-6-methyl-4-(3H)pyrimidinone, ABMP) induced
circulating levels of interferon (IFN) in several animal specis upon oral or intraperitoneal
administration.114 Subsequent structure-activity studies yielded a more potent and
less toxic 6-phenyl ananlog called ABPP or bropirimine (2-amino-5-bromo-6-phenyl-
4-(3H)pyrimidinone) (figure 1 and Table 1).115,116 Bropirimine and related  6-aryl
analogs were examined extensively for efficacy in virus and tumor models, along













     Figure 1 :  Preliminary SAR of antiviral activity of pyrimidinones
                                     
(underlined substituents were active)



















         Antiviral  activity
monosubstituted Disubstituted Heterocyclic
Active         2-F,OMe, Me 3,5-OMe 1-Naphthyl
          3-F,OMe, Cl, NO2 2,5-Cl2 2-Pyrazyl
Me, CF3, MeCH2CH2O, 3,5-OMe 2,3-pyridyl
Br,I 3,4-Cl2 2-Furyl
4-F, Cl 3,5-Cl2
Inactive 4-Me, CN, But, 2,3-OMe 2-Napthyl
OH,OCH2ph, OMe 1-Furyl
4-Pyridyl
                                         2-Quinoline
As with the polynucleotides, the pyrimidinones exhibited significant
activity against interferon (IFN) sensitive viruses such as Semliki Forest virus in vivo.
However, in addition, they exhibited prophylactic and therapeutic activity upon
either local or systemic administration to rodents infected with a variety of DNA
viruses, such as the herpes viruses (HSV-1, HSV-2 , CMV  and pseudorabies) ,
and when administered intranasally for upper respiratory infections, such as
infectious bovine rhinortacheites, influenza A and para-influenza-3. Particularly
interestion activity was noted  with bropirimine on intravaginal administration in
protection against HSV-2 intravaginal infection in guinea pigs, an important model
for genital herpes in humans.118 Bropirimine  also exhibited activity when given
either intraperitoneally or orally to mice infected with Listera monocytogenes. The
efficacy in this model  was not abrogated by the addition of anti-interferon (IFN)
antibody. 119
Pyrimidines as Antifolates
        During a preliminary clinical trial designed to establish safety and suitability
for use in the treatment of cancer, Farber found the folic acid derivatives
pteroyldiglutamic acid (17) and pteroyltriglutamic acid  (18) were accelerating
the growth of malignant cells in the bone marrow of patients with acute leukaemia.
He obtained the newly synthesized antifolate pteroylaspartic acid from Subba Row,
from which encouraging results were obtained in children with acute leukaemia.
Better responses were observed with the aminopterin (19) and methotrexate(20).
Injections of methotrexate induced temporary remissions in 30% of children, but
Table I
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Farber and his colleagues later combined it with drugs such as cortisone
and mercaptopurine to achieve results which paved the way towards the
currentposition where most children can be cured of the disease if given the ap-
propriate treatment. The precise model of action of the antifolates became ap-
parent in 1952. This was the inhibition of dihydrofolate reductase , the enzymes
that catalysed the transformation of folic acid so that it could be utilized for the
synthesis of thymine  for incorporation into  DNA. Surprisingly, no other antifolate
















(17)   n = 0, R = NHCH(COOH)CH2CH2COOH
(18)   n =2,  R = OH
(19)    R = H











5-Azacytidine ( Azacitidine; 21)  the most active of the azapyrimidines ,
shows substantial activity in the treatment of murine and human leukaemas, but
little useful activity against solid tumours.120 It is phosphorylated in vivo  to the
mono-,di- and tri- phosphate levels, and inhibits nucleic acid synthesis and function.
In calf thymus nuclei, the synthesis of mRNA is inhibited, while the incorporation
of 5-azacytidine  into tRNA decreases amino acid acceptor activity for most of
the amino acids , further suppressing protein synthesis.121
5-Azauracil  (22) and 5-azaorotic acid (23) are competitive inhibitors of
orotate phosphoribosyltransferase122 and show activity against adenocarci-
noma 755, but not against LI210 leukaemia.
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6-Azauridine (24) was formerly used to treat chronic myelogenous and
acute leukaemias123, as well as psoriasis and mycosal infection. For the latter
conditions, it was applied as its prodrug 2’,3’,5’-tri-O-acetyl-6-azauridine
( Azaribine; 25) which has been withdrawn from the market. 6-Azauridine  is phos-
phorylated in vivo to it’s 5’-monophosphate, which inhibits orotidylic acid
metabolism, is primarily responsible for it’s cytotoxic effects.
Of the various halogenated pyrimidines which have been prepared, only
the fluorinated pyrimidines and nucleosides have useful antitumour activity, and
of these the most significant are 5-fluorouracil (FU) and it’s 2’-deoxyribo-
nucleside (FUdR; Floxuridine). Both of these drugs have found wide uses in
patients suffering from metastatic cancer, and have been administered both sin-
gly and in combination therapy.
The presence of flourine, which cannot be abstracted by base, halts the
process. In contrast, the 5’-monophosphate  of 5- chloro-, 5- bromo- and 5-iodo-
2’-deoxyuridine, in which the halogen atom is bulkier and less electronegative,
have little or no useful inhibitory activity for the enzyme. The drugs of fluorouracil
(FU) showing good antitumour activity includes it’s 1-t-butylcarbamoyl124,1-
hexylcarbamoyl125 and 1-methoxycarbonylmethylcarbamoyl126derivatives,
5’-deoxy-5-fluorouridine127 and methyl-1-(5-fluoro-1-H-2-oxopyrimidin -4-yl)-
B-D-glucopyranuronate  (26).128 All of these contain in essence the fluorou-
racil (FU)  moiety, ready via oxidative or hydrolytic means. 5-Fluoropyrimidin-4(1H)-
one, with activity against tumours in experimental animals, is a different type of























     (21)                    (22) R = H        (24)     R = H
(23) R = COOH         (25)     R = MeCO
Antagonist  : A chemical substance that interferes with the physiological action of another, especially by
         combining with and blocking its nerve receptor.
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A number of prodrugs of FUdR have also been prepared a notably potent
member being 5-bromo-6-methoxydihydro-5-fluro-2’-deoxyuridine  (27).130
finally, a different species of fluoro-pyrimidine  derivative, which as its 5’-mono-
phosphate  inhibits thymixylate synthetase is 5-trifluoromethyl-2’-deoxyuridine
( Trifluridine ; 28)  it possesses a higher therapeutic index against adenocarci-
noma 755 in mice than 2’-deoxyribo-nucleoside (FUdR; Floxuridine) .131

























PYRIMIDINES AS ANTITUMOUR AGENTS
A number of other pyrimidine antagonists displaying antitumour activity, in
which the base is conjugated to a modified suger ring have been reported.
Although D-Arabinofuranosyl uridine (ara-uridine)  shows no useful acitivity,
and 5-bromo-and 5-iodo-D-arabinofuranosyl uridine inhibit the growth of  sarcoma
180 and L1210 cells in culture.132 Other thymidine analogues with similar activity
inc lude  5 -az idomethy l - , 5 -aminomethy l and  5 -hydroxymethy l -2 ’ -
deoxyuridine 133. 3’-Amino-3’-deoxy thymidine134 and 3’-amino-2’,3’-
dideoxycytidine135 also posses strong activity against L1210 leukaemia 2’-
Deoxy-2’-fluoro-5-methyl-1-B-D-arabinofuranosyluracil (FMAU; 29)  is highly
active against arabinofuranosyl cytidine (ara-C) resistant L1210 and P815 cell lines
both in vitro and in vivo.136 2-B-D-Ribofuranosylthiazole-4-carboxamide
(Tiazofurin; 30) has aroused much interest recently for its activity against solid
tumour such as lung carcinoma. It is metabolized to an analogue of NAD  in which
the thiazole-4-carboxamide  moiety replaces the nicotinamide  ring. However, it
also depresses the synthesis of DNA  and RNA , and thus merits inclusion as an
antagonist of normal purine  and pyrimidine metabolism.137
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Targets for Antiviral Chemotherapy
Viral chemotherapy presents a quite different problem from tumour
chemotherapy. A virus138 consists of a core of nuclear material, DNA  or RNA ,
containing specific viral genes, which may be associated with ‘core proteins’,
and which is surrounded by a protective proteincoat. The coat may have functional
protein appendages, and there may be present an ‘envelope’, rich in lipoprotein
and glycoprotein. The virus possesses no energy-producing or protein-synthesizing
machinery of its own. In order to reproduce, it must therefore become adsorbed
to a host cell, be transported across the cell membrane, and uncoat in order that
its viral genes may be expressed. The genome may require to be transported to
the cytoplasm or the nucleus. The nuclear material must then be replicated, and
the viral genes also transcribed into RNA  (assuming that we are dealing with a
DNA  virus) and  translated into virally specified protein. In addition to the coat
protein, viral enzymes will be produced in this process, and these are vital for
suborning the host cell’s internal biochemistry to serve the requirements of the
virus. Before the viral proteins can be made, a process of maturation of the viral
mRNA molecules, involving guanylylation and methylation to produce a ‘cap’ struc-
ture containing 7-methylguanosine 5’-phosphate in a 5’- 5’-pyrophosphate
structure at the 5’- end of the mRNA, must occur. Once the synthesis of the
components needed to make fresh viral particles has been completed, maturatian
occurs, in which the nucleic acid and protein components are assmbled to from
the complete viral particle or virion, and finally this is released from the cell as a
new , infective virus. RNA  viruses require that their nucleic acid be replicated
also, in order that new viral particles can form. Some RNA  viruses code for an
enzyme ‘transcriptase’ or ‘replicase’ (RNA -directed RNA polymerase), which
replicates RNA  strands directly without involving DNA139 while others encode
an enzyme ‘reverse transcriptase’ ( RNA  -directed DNA  polymerase), which tran-
scribes the RNA  sequence into DNA -the reverse of the usual sequence which
can subsequently become integrated into the host cell chromosome and is tran-
scribed to from copies of the viral RNA.140 Purine and pyrimidine antimetabolites
which are active against viruses are thus most likely to be effective by inhibiting
specifically the viral enzymes which are required to replicate the viral nucleic
acids, or inhibiting the viral enzymes responsible for transcription and capping of
mRNA,without  inhibiting the corresponding enzymes of the host cell.
Agonist : A drug which binds to a receptor and activates it, producing a pharmacological response.
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Alternatively, incorporation of an antimetabolite into a viral nucleic acid
causing the cessation of strand synthesis, or otherwise disturbing the normal function
of the nucleic acid in replication or in directing protein synthesis, offers another
way of preventing the replication of functional virus.141 Again, it is important that
the integrity of the nuclear material of the host cell should not be compromised.
One therefore seeks to exploit the differences between the viral enzymes to the
discomfiture of the virus.
5’- Amino-5-iodo-2’,5’-dideoxyuridine(Aminoidoxuridine; 32) displays good
antiherpes activity and is less cytotoxic than (31).142,143 The phosphorylation
of Aminoidoxuridine(32) is catalyzed specifically by virus-induced thymidine kinase,
and thus Aminoidoxuridine(32) is only potentiated in virus-infected cells. It inhibits
the synthesis of DNA  in infectedcells. The 5-bromo-, 5-chloro- and 5-trifluoro-
methyl derivatives of 5’-amino-2’,5’-dideoxyuridine also exhibit antiviral
activity144. 5-Iodo-2’-deoxcytidine (33) and 5-bromo-2’-deoxycytidine (34) also
show useful activity against herpes viruses and vaccinia with less cytotoxicity than
the uridine  compounds and more selective inhibition of virus replication.
PYRIMIDINES AS ANTI-HIV AGENTS
The strategy of designing nucleoside analogs that are selective for viral
DNA  polymerases is the most well-studied and successful approch to viral
chemotherapy, and has led to the discovery of several clinically useful antiviral
drugs. This strategy, however, has inherent limitations. Human DNA  polymerases
also required dNTP’s and the chemical mechanisms of polymerization by the viral
and human enzymes are similar. Nucleoside analogs often have significant host
toxicity that is probably related to inhibition of host cell DNA synthesis. Nevertheless,
         (29)                        (30)                    (31)  R= OH        (33)  X= I
































these compounds constitute the major class of antiviral drugs, and this approach
is likely to yield additional active compounds in the near future. For the long
term,however, other strategies may ultimately lead tonmmore selective agent withn
lower toxicity.
Obviously, the key to design analogue with a lower affinity for the host enzyme
than the viral enzyme, which requires that there be structural differences between
the enzyme active sites. For reverse transcriptase, the most well studied inhibitor
is 3’-azido-3’-deoxythymidine (AZT;  35), which is currently used clinically to treat
AIDS.145,146
3’-azido-3’-deoxythymidine (AZT)  inhibits HIV reverse transcriptase with
an IC50 of 40nM 147 , but is 100-300 times less active against mammalian DNA
polymerase a  and DNA  polymerase g . The reason for this selectivity is not clear
since 3’-azido-3’-deoxythymidine (AZT)  is a chain terminator for mammalian
DNA  polymerases and inhibits normal cellular DNA  synthesis.148  Several other
dideoxynucleoside analogs have been shown to be potent inhibitors of HIV
replication in vitro.149,150 In general, these compounds have the same mechanism
of action as 3’-azido-3’-deoxythymidine (AZT), that is, intracellular conversion
to the triposphate derivative and subsquent inhibition of HIV reverse transcriptase.
Some of these compounds are simply analogs of the nautral 2’-deoxy-
nucleoside in which the 3’-OH  group has been replaced with a hydrogen, such
as 2’,3’-dideoxycytidine(36 ), 2’,3’-dideoxyadenosine(37) and 2’,3’-dideoxy
thymidine(38). Other analogs contain a 2’-3’ double bond, such as 2’3’-
didehydro-2’,3’-dideoxythymidine (39). Several related analogs with other
modifications to the ribose ring or the heterocyclic base moiety have also been




































                       (36)              (37)                (38)             (39)
Recently, P. Khalili et al.153 have carried out biochemical and pharmaco-
kinetic evaluation of a novel nitric oxide  donor pyrimidine nucleoside hybrid
drug as a potential anticancer / antiviral agent. Rostom et al.154 have synthesized
and screened certain 2-(benzoxazol-2-yl-amino)-3H-4-oxopyrimidines for
in-vitro anti-HIV  activity.
A family of trisubstituted pyrimidines has been described as selective
COX-2 inhibitors. To explore the usefulness of pyrimidine derivatives as potential
NSAIDs. Aurelio Orjales et al155 have synthesized novel pyrimidine derivatives
40 and 41. In vitro biological evaluation of these compounds has provided     in-












40.  Y = CH; X,Z = N
41.  Y,Z = N; X = CH
In view of procuring highly potent biodynamic agents and after reviewing
recent literature survey on 2-hydroxy / mercapto / amino pyrimidines  for their
various methods of synthesis and different pharmacological activities, synthesis
of pyrimidines  have been undertaken which can be summarized in the following
sections as  follows:
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SECTION - I :    PREPARATION AND BIOLOGICAL EVALUATION OF 2-
                            MERCAPTO-4-AMINO-5-CYANO-6-(1’-N-PHENYL-3’-ARYL-
                            PYRAZOL-4’-YL)-1,6-DIHYDRO PYRIMIDINES.
SECTION - II :   PREPARATION AND BIOLOGICAL EVALUATION OF 2-
                            HYDROXY-4-AMINO-5-CYANO-6-(1’-N-PHENYL-3’-ARYL-
                            PYRAZOL- 4’-YL)-1,6-DIHYDRO PYRIMIDINES.
SECTION -III : PREPARATION AND BIOLOGICAL EVALUATION OF2,4-
                            DIAMINO-5-CYANO-6-(1’-N-PHENYL-3’-ARYL-PYRAZOL-
                            4’-YL)-1,6-DIHYDRO PYRIMIDINES.
SECTION - IV :  PREPARATION AND BIOLOGICAL EVALUATION OF
                             2- MERCAPTO METHYL-4-AMINO-5-CYANO-6-(1’-N-PHENYL-
                            3’-ARYL-PYRAZOL-4’-YL)-1,6-DIHYDRO PYRIMIDINES.
SECTION - V :   PREPARATION AND BIOLOGICAL EVALUATION OF
                             2- METHYL SULPHONYL-4-AMINO-5-CYANO-6-(1’-N-PHENYL-
                            3’-ARYL-PYRAZOL-4’-YL) PYRIMIDINES.
SECTION - VI :  PREPARATION AND BIOLOGICAL EVALUATION OF
                             2- [(2’’,4’’-DINITROPHENYL)-THIO]-4-AMINO-5-CYANO-6-(1’-N-
                                 PHENYL-3’-ARYL-PYRAZOL-4’-YL) -1,6-DIHYDRO PYRIMIDINES.
SECTION - VII :  PREPARATION AND BIOLOGICAL EVALUATION OF
                             2- [(2’’,4’’-DINITROPHENYL)-SULPHONYL]-4-AMINO-5-CYANO-
                                6-(1’-N-PHENYL-3’-ARYL-PYRAZOL-4’-YL) PYRIMIDINES.
SECTION - VIII :  PREPARATION AND BIOLOGICAL EVALUATION OF
                              2- [(2’,4’-DINITROPHENYL)-SULPHONYL]-4-AMINO-5-CYANO-6-
                                 ARYL PYRIMIDINES.
37Studies on Pyrimidines
SECTION - I
PREPARATION AND BIOLOGICAL EVALUATION OF 2-MERCAPTO-4-AMINO-
5-CYANO-6-(1’-N-PHENYL-3’-ARYL-PYRAZOL-4’-YL)-1,6-DIHYDRO PYRIMIDINES
Due to  biodynamic act iv i t ies 47-10 6 of pyrimidines and with a view
to have potent therapeutic agents, the synthesis of 2-mercapto-4-amino-5-cy-
ano-6-(1’-N-phenyl-3’-aryl-pyrazol-4’-yl)-1,6-dihydro pyrimidines (Ia-h) have
been undertaken by the condensation of different 3-aryl-1-N-phenyl-pyrazol-4-







The constitution of the products (Ia-h ) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (Ia-h ) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml):  0 (control) , 5, 10, 25, 50, 100, 200, 500  for their MIC (Minimum Inhibi-
tory  Concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
(Ia-h)                                              R=Aryl
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   IR SPECTRAL STUDY OF  2-MERCAPTO-4-AMINO-5-CYANO-6-(1’-N-
  PHENYL-3’-(p-METHOXY PHENYL) -PYRAZOL-4’-YL)-1,6-DIHYDRO-















 C=C + C=N and
ring  skeletal  vibration
 C-H str.
 C-H i.p. def.
 C-H o.o.p. def.
 C-O-C str. (asym.)
 C-O-C str. (sym.)
 N-H str.
 N-H def.
 Cº N  str
 C=N  str
 N -N  def
 C -N str
Frequency in cm-1
Observed
   2923.9
   2852.5
   1440.7
   1346.2
   1494.7
   1521.7
   3087.8
   1093.6
     825.5
   1255.6
   1074.3
   3350.1
   1623.9
   2208.3
   1645.2
   1579.6
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PMR SPECTRAL STUDY OF  2-MERCAPTO-4-AMINO-5-CYANO-6-(1’-N-
PHENYL-3’- (p-METHOXY PHENYL) -PYRAZOL-4’-YL)-1,6-DIHYDRO
PYRIMIDINE  (Ib)
       1
       2
       3
       4
       5
       6
       7
  Signal
    No
    Signal position
      (d  ppm)
    Relative No.
     of Protons    Multiplicity       Inference
         3.922
         6.720
      7.0825-7.111
      7.506-7.534
      7.574-7.619
         8.367
         8.955
       3H
       1H
       2H
       2H
       5H
       1H
       1H
    singlet
    singlet
   doublet
   doublet
   multiplet
   singlet










































































































































































































































                                                           REACTION SCHEME
                                                                         ( Ia-h )                          R=Aryl
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 2-MERCAPTO-4-
AMINO-5-CYANO-6-(1’-N-PHENYL-3’-ARYL-PYRAZOL-4’-YL)-1,6-DIHYDRO
PYRIMIDINES.
(A) Preparat ion of 2-Mercapto-4-amino-5-cyano-6-(1’-N-phenyl-3’-
          (p-methoxy phenyl)-pyrazol-4’-yl)-1,6-dihydro pyrimidine.(Ib).
A mixture of 1-N-phenyl-3-(p-methoxy phenyl) pyrazol-4-carboxaldehyde
(2.78gm, 0.01 M), malononitrile(0.66 ml, 0.01 M) and thiourea (0.76 gm, 0.01 M) in
ethanol(30 ml) was heated under refluxed condition for three hrs. Then the reac-
tion mixture was kept at room temperature for two hrs. The yellow crystalline product
was obtained. The product was isolated and recrystallized from ethanol. Yield :
63%, M.P. : 165°C, Rf1
 : 0.59, Rf2
 : 0.51 (Required : C, 62.68%; H, 4.47%;
N, 20.89% for C 21H18N6OS, Found : C, 62.62%; H, 4.42%; N, 20.84%)
Similarly, other compounds (Ia-h ) were synthesized. The physical data are
recorded in Table No.1.
(B) Antimicrobial activity of 2-Mercapto-4-amino-5-cyano-6-(1’-N-phenyl-
            3’-aryl-pyrazol-4’-yl) -1,6-dihydro pyrimidines. (Ia-h )
Antimicrobial activity testing was carried out by using cup-plate method156,
which has been described as under.
     * Antibacterial activity
S. pyogens MTCC-442 and S. aureus MTCC-96 (Gram posit ive
bacteria) were grown in nutrient broth and E. coli MTCC-443 and B. subtillis
MTCC-441 (Gram negative bacteria) in Peptone water (PW, 1% bacteriological
peptone and 0.5% NaCl) for 24 hrs., this gave an optimum growth of the test
bacteria. Each purified compound was dissolved in dimethyl formamide (DMF)
sterilized by filtration by using sintered glass filter and stored at 4°C. Each agent
was then added to molten nutrient agar in the following concentrations.
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(µg/ml) :  0 (control), 5, 10, 25,50, 100, 200, 500  and poured into sterile petri
dished. The pH of the media was maintained at 7.2 to7.4. The inoculum con-
sisted of an overnight grown broth culture of a bacterium diluted in such a manner
that a 2 mm (internal diameter) loopful of the culture contain 105 colony-forming
unit (CFU). These were then spot inoculated on nutrient  agar  plates containing
increasing amount of a  compound, incubated at 37°C up to 24 hrs. for determi-
nation of the minimum inhibitory concentration157,158  (MIC). Which are recorded
in zones of inhibition in mm for bacterias.
   * Antifungal activity
C. albicans MTCC-227 and A. niger MTCC-282 was employed for
testing antifungal activity using cup-plate method. The culture was maintained on
Sabouraud's agar for 72 hrs., this gave an optimum growth of the test fungal
spores. Each purified compound was dissolved in dimethyl formamide (DMF) ster-
ilized by filtration by using sintered glass filter and stored. Each agent was then
added to Sabouraud's agar in the following concentrations (µg/ml):  0 (control),
5, 10, 25, 50, 100, 200, 500  and poured into sterile petri dished. The inoculum
consisted of an overnight grown broth culture of a bacterium diluted in such a
manner  than a 2 mm (internal diameter) loopful of the culture contain 105 colony-
forming unit (CFU). These were then spot inoculated on Sabouraud's agar plates
containing increasing amount of a compound, incubated at 37°C up to 48 hrs. for
determination of the minimum inhibitory concentration (MIC)157,158. The MIC
values of test solutions are recorded in Table No. 1a, 1b & 1c .  Which are re-









































































































































































   
   
   
   
   
0.
54
   
   
   
0.
48
   
   






























   
   
   
   
   
0.
59
   
   
   
0.
51
   
   































   




   
   































   




   
   
































   




   
   






























   




   
   































   




   
   
































   




   
   









































   
   
   
   
   
   
   














   







   
  R
f 1
   















































































































































































































































































































   
   





































   
   
   
   
   
   
   
   
   



























































































































































































































































































































































































I e I f
I a I b I e
I f
47Studies on Pyrimidines








































































































































































































































































   
   





































   
   
   
   
   
   
   
   
   


































































































































































































































































































































































































































































































































































































































   
   





































   
   
   
   
   
   
   
   
   




















































































































































































































































































































































































PREPARATION AND BIOLOGICALEVALUATION OF 2-HYDROXY-4-AMINO-5-
CYANO-6-(1’-N-PHENYL-3’-ARYL-PYRAZOL-4’-YL)-1,6-DIHYDRO PYRIMIDINES.
Due to  biodynamic act iv i t ies 47-10 6 of pyrimidines and with a view
to have potent therapeutic agents, the synthesis of 2-hydroxy-4-amino-5-cyano-
6-(1’-N-phenyl-3’-aryl-pyrazol-4’-yl)-1,6-dihydro  pyrimidines (IIa-h ) have been
undertaken by the condensation of different 3-aryl-1-N-phenyl-pyrazol-4-







The constitution of the products (IIa-h) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (IIa-h ) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) :  0 (control), 5, 10, 25, 50, 100, 200, 500  for their MIC (Minimum In-
hibitory  Concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
(IIa-h)                                               R=Aryl
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  IR SPECTRAL STUDY OF 2-HYDROXY-4-AMINO-5-CYANO-6-(1’-N-PHENYL-
  3’-(p-METHYL PHENYL)-PYRAZOL-4’-YL)-1,6-DIHYDRO PYRIMIDINE. (IIc)
     Type
 Alkane
 CH3












 C=C + C=N and ring
skeletal  vibration
 C-H str.
 C-H i.p. def.




 CºN  str.
 C=N  str.
 N -N  def.
 C -N str.
Frequency in cm-1
Observed
   2922.0
   2867.9
   1458.1
   1321.1
   1514.0
   1568.0
   3031.9
   1112.8
     833.2
   3450.4
   3348.2
   1593.1
   2208.3
   1606.6
   1656.7
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PMR SPECTRAL STUDY OF 2-HYDROXY-4-AMINO-5-CYANO-6-(1’-N-PHENYL-
3’-(p-METHYL PHENYL)-PYRAZOL-4’-YL)-1,6-DIHYDRO PYRIMIDINE. (IIc)
       1
       2
       3
       4
       5
       6
  Signal
    No
    Signal position
      (d  ppm)
    Relative No.
     of Protons    Multiplicity       Inference
         2.452
        7.334-7.360
        7.403-7.552
        7.784
      7.792-7.819
         9.030
       3H
       2H
       5H
       1H
       2H
       1H
    singlet
   doublet
   multiplet
   singlet
  doublet
   singlet
 -CH3(a)
 Ar-H (b,b’) (J=7.8)
 Ar-H
 Ar-H (c)






















































































































































































































































                                                REACTION SCHEME
                                                                                        (IIa-h) R=Aryl
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 2-HYDROXY-4-AMINO-
5-CYANO-6-(1’ -N-PHENYL-3’-ARYL-PYRAZOL-4’-YL)-1,6-DIHYDRO
PYRIMIDINES.
(A) Preparat ion of  2-Hydroxy-4-amino-5-cyano-6-(1’-N-phenyl-3’-
(p-methylphenyl)-pyrazol-4’-yl) -1,6-dihydro pyrimidine. (IIc).
A mixture of 1-N-phenyl-3-(p-methyl phenyl)- pyrazol-4-carboxaldehyde
(2.62gm, 0.01 M), malononitrile(0.66 ml, 0.01 M) and urea (0.6 gm, 0.01 M) in
ethanol(30 ml) was heated under refluxed condition for three hrs. Then the
reaction mixture was kept at room temperature for two hrs. The yellow crystalline
product  was obtained. The product was isolated and recrystallized from
ethanol. Yield : 62%, M.P. : 160°C, Rf1
 : 0.63, Rf 1
 :  0.53 (Required :
C, 68.11%; H, 4.86%; N, 22.70% for C21H18N6O, Found : C, 68.06%; H,
4.80%; N, 22.65%)
Similarly, other compounds (IIa-h ) were synthesized. The physical data are
recorded in Table No.2.
(B)    Antimicrobial activity of 2-Hydroxy-4-amino-5-cyano-6-(1’-N-phenyl-
            3’-aryl-pyrazol-4’-yl) -1,6-dihydro pyrimidines. (IIa-h )
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 43. The MIC values of test solution are recorded in Table No.
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PREPARATION AND BIOLOGICALEVALUATION OF 2,4-DIAMINO-5-CYANO-
6-(1’-N-PHENYL-3’-ARYL-PYRAZOL-4’-YL)-1,6-DIHYDRO PYRIMIDINES.
Due to biodynamic act iv i t ies 47-10 6 of pyrimidines and with a view to
have potent therapeutic agents, the synthesis of 2,4-diamino-5-cyano-6-(1’-N-
phenyl-3’-aryl-pyrazol-4’-yl)-1,6-dihydro pyrimidines (IIIa-h ) have been under-
taken by the condensat ion o f  d i f ferent  3-aryl-1-N-phenyl pyrazol-4-







The constitution of the products (IIIa-h ) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (IIIa-h ) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) :  0 (control), 5, 10, 25, 50, 100, 200, 500  for their MIC (Minimum In-
hibitory  Concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
( IIIa-h )                                           R=Aryl
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  IR SPECTRAL STUDY OF 2,4-DIAMINO-5-CYANO-6-(1’-N-PHENYL-3’-
 (p-METHOXY PHENYL)-PYRAZOL-4’-YL)-1,6-DIHYDRO PYRIMIDINE  (IIIb)
      Type
 Alkane
 CH3












 C=C + C=N and ring
skeletal  vibration
 C-H str.
 C-H i.p. def.
 C-H o.o.p. def.
 C-O-C str. (asym.)
 C-O-C str. (sym.)
 N-H str.
 N-H def.
 CºN  str.
 C=N  str.
 N -N  def.







































































   2925.8
   2854.5
   1442.7
   1346.2
   1512.1
   1541.1
   3082.0
   1114.8
     810.0
   1247.9
   1078.1
    3408.0
    1606.6
    2218.0
   1623.9
    1651.0
    1215.1
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PMR SPECTRAL  S T U D Y OF 2 ,4-DIAMINO-5-CYANO-6-(1’-N-PHENYL-
3’-(p-METHOXY PHENYL)-PYRAZOL-4’-YL)-1,6-DIHYDRO PYRIMIDINE (IIIb)
       1
       2
       3
       4
       5
       6
  Signal
    No
    Signal position
      (d  ppm)
    Relative No.
     of Protons    Multiplicity       Inference
         3.893
        7.078-7.049
        7.453-7.556
        7.781
      7.793-7.820
         9.028
       3H
       2H
       5H
       1H
       2H
       1H
    singlet
   doublet
   multiplet
   singlet
   doublet
    singlet
 -OCH3(a)
 Ar-H (b,b’) (J=8.7)
 Ar-H
 Ar-H (c)















































































































































































































                                                          REACTION SCHEME
          (IIIa-h ) R=Aryl
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 2,4-DIAMINO-5-CYANO-
6-(1’-N-PHENYL-3’-ARYL-PYRAZOL-4’-YL)-1,6-DIHYDRO PYRIMIDINES.
(A) Preparation of 2,4-Diamino-5-cyano-6-(1’-N-phenyl-3’-(p-methoxy
phenyl)-pyrazol-4’-yl) -1,6-dihydro pyrimidine. (IIIb)
A mixture of 1-N-phenyl-3-(p-methoxyphenyl)-pyrazol-4-carboxaldehyde
(2.78gm, 0.01 M),malononitrile(0.66 ml, 0.01 M) and guanidine hydrochloride
(0.96 gm, 0.01 M) in ethanol(30 ml) was heated under refluxed condition for three
hrs. Then the reaction mixture was kept at room temperature for two hrs. The
yellow crystalline product  was obtained. The product was isolated and recrystal-
lized from ethanol. Yield : 60%, M.P. : 108°C, R f1
 : 0.68,  R f2
 : 0.49 (Required
:C, 65.45%;  H, 4.93%; N, 25.45% for C21H19N7O, Found : C, 65.40%; H,
4.88%; N, 25.41%)
Similarly, other compounds (IIIa-h ) were synthesized. The physical data
are recorded in Table No.3.
(B)    Antimicrobial activity of 2,4-Diamino-5-cyano-6-(1’-N-phenyl-3’-aryl-
         pyrazol-4’-yl)-1,6-dihydro pyrimidines (IIIa-h ).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 43. The MIC values of test solution are recorded in Table No.
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PREPARATION AND BIOLOGICALEVALUATION OF  2-MERCAPTO METHYL-
4-AMINO-5-CYANO-6-(1’-N-PHENYL-3’-ARYL-PYRAZOL-4’-YL)-1,6-DIHYDRO
PYRIMIDINES.
Looking to biodynamic activities47-106 of pyrimidines and with a view to
have potent therapeutic agents, the synthesis of  2-mercaptomethyl-4-amino-5-
cyano-6-(1’-N-phenyl-3’-aryl-pyrazol-4’-yl)-1,6-dihydro pyrimidines (IVa-h)
have been undertaken by the condensation of 2-mercapto-4-amino-5-cyano-6-
(1’-N-phenyl-3’-aryl-pyrazol-4’-yl)-1,6-dihydro pyrimidines   with dimethyl sul-








The constitution of the products (IVa-h) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (IVa-h) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) :  0 (control), 5, 10, 25, 50, 100, 200, 500  for their MIC (Minimum In-
hibitory  Concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
( IVa-h )                                             R=Aryl
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   IR SPECTRAL STUDY OF 2-MERCAPTO METHYL- 4-AMINO-5-CYANO-6-
  (1’- N- PHENYL-3’-(p-METHOXY PHENYL)-PYRAZOL- 4’-YL)-1,6-DIHYDRO
  PYRIMIDINE  (IVb)
      Type
 Alkane
 CH3













 C=C + C=N and ring
skeletal  vibration
 C-H str.
 C-H i.p. def.
 C-H o.o.p. def.
 C-O-C str. (asym.)
 C-O-C str. (sym.)
 N-H str.
 N-H def.
 CºN  str.
C=N  str.






















   700-600
   2923.9
   2869.9
   1465.8
   1346.2
   1490.9
   1554.5
   3060.8
   1105.1
     821.6
   1257.5
   1074.3
    3348.2
    1645.2
    2206.4
    1602.7
    1629.7
    1028.0
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PMR SPECTRAL STUDY OF 2-MERCAPTO METHYL-4-AMINO-5-CYANO -
6-(1’-N-PHENYL-3’-(p-METHOXY PHENYL)-PYRAZOL-4’-YL)-1,6-DIHYDRO
PYRIMIDINE  (IVb)
       1
       2
       3
       4
       5
       6
       7
  Signal
    No
    Signal position
      (d  ppm)
    Relative No.
     of Protons    Multiplicity       Inference
         2.440
         3.897
      7.345-7.369
      7.418-7.518
      7.812-7.838
         8.305
         9.123
       3H
       3H
       2H
       5H
       2H
       1H
       1H
    singlet
    singlet
   doublet
   multiplet
   doublet
    singlet





















































































































































































































































                                              REACTION SCHEME
  (IVa-h)                R=Aryl
   (Ia-h )
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 2-MERCAPTO
METHYL-4-AMINO-5-CYANO-6-(1’-N-PHENYL-3’-ARYL-PYRAZOL-4’-YL)-
1,6-DIHYDRO  PYRIMIDINES
(A) Preparation of 2-Mercapto-4-amino-5-cyano-6-(1’-N-phenyl-3’-
(p-methoxy phenyl)-pyrazol-4’-yl) -1,6-dihydro pyrimidine. (Ib)
For preparation refer part-I,section-I, page no.43.
(B) Preparation of 2-Mercapto methyl-4-amino-5-cyano-6-(1’-N-phenyl-3’-
         (p-methoxy phenyl)-pyrazol-4’-yl) -1,6-dihydro pyrimidine (IV b).
 A mixture of 2-Mercapto-4-amino-5-cyano-6-(1’-N-phenyl-3’-(p-methoxy
phenyl)-pyrazol-4’-yl) -1,6-dihydro pyrimidine  (3.86gm, 0.01 M), and dimethyl
sulphate(1.26 ml, 0.01 M)  in ethanol(30 ml)and 40% aqueous  sodium hydrox-
ide was stirred for 12 hrs.at room temperature. The content was poured into ice
cold water and filtered. The product was isolated and crystallized from ethanol.
Yield : 52%, M.P. : 180°C, Rf1
 : 0.63, Rf2
 : 0.57 (Required : C, 63.46%; H,
4.81%; N, 20.19% for C22H20N6OS, Found :C, 63.41%; H, 4.75%; N,
20.12%)
Similarly, other compounds (IVa-h) were synthesized. The physical data
are recorded in Table No.4.
(C)    Antimicrobial activity of  2-Mercapto methyl-4-amino-5-cyano-6-(1’-
           N- phenyl-3’-aryl-pyrazol-4’-yl) -1,6-dihydro pyrimidines  (IVa-h)
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No.43. The MIC values of test solution are recorded in Table No.
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SECTION - V
PREPARATION AND BIOLOGICAL EVALUATION OF 2-METHYL
SULPHONYL-4-AMINO-5-CYANO-6-(1’-N-PHENYL-3’-ARYL-PYRAZOL-4’-
YL) PYRIMIDINES.
In view of various biodynamic activities47-106 of  pyrimidines and in or-
der to have highly potent therapeutic agents, the synthesis of 2-methylsulphonyl-
4-amino-5-cyano-6-(1’-N-phenyl-3’-aryl-pyrazol-4’-yl)-pyrimidines(Va-h) have been
undertaken by the reaction of 2-mercaptomethyl-4-amino-5-cyano-6-(1’-N-phe-
nyl-3’-aryl-pyrazol-4’-yl)-1,6-dihydro pyrimidines  with hydrogen peroxide .
The constitution of the products (Va-h) have been delineated by elemen-
tal analyses, IR, PMR  and Mass spectral data.
The products (Va-h) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500  for their MIC (Minimum In-
hibitory  Concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
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      Type
  Alkane
 CH3
  Aromatic and
  Pyrimidine











 C=C + C=N and ring
skeletal  vibration
 C-H str.
 C-H i.p. def.
 C-H o.o.p. def.
  N-H str.
  N-H def.
  CºN  str.
  C=N  str.
  N -N  def.
  C -N str.
  S=O str. (asym.)




















   2923.9
   2875.7
   1450.4
   1317.3
   1479.3
   1558.4
   3068.5
   1101.3
     815.8
    3446.6
    1593.1
    2204.5
    1633.6
    1652.9
    1049.2
     1342.4
     1143.7
  IR SPECTRAL STUDY OF 2-METHYLSULPHONYL-4-AMINO-5-CYANO-6-








































    374
     ,,
     ,,
     ,,
    375
     ,,
     ,,
     ,,
     ,,
    376
      ,,
      ,,
      ,,
    374
      ,,
    376
      ,,
Studies on Pyrimidines 84
PMR SPECTRAL STUDY OF 2-METHYLSULPHONYL-4-AMINO-5-CYANO-
6-(1’-N-PHENYL-3’-(p-METHYL PHENYL)-PYRAZOL-4’-YL) PYRIMIDINE (Vc)
       1
       2
       3
       4
       5
       6
  Signal
    No
    Signal position
      (d  ppm)
    Relative No.
     of Protons    Multiplicity       Inference
         2.168
         2.454
      7.364-7.399
      7.443-7.492
      7.793-7.824
         9.039
       3H
       3H
       2H
       5H
       2H
       1H
    singlet
    singlet
   doublet
   multiple
  doublet









































































































































































































































(M -1) (M -1) (M -1) (M -1)
(M -1) (M +1)
(M +1)





































                                                     REACTION SCHEME
(Va-h)                          R=Aryl
(IVa-h)
   (Ia-h)
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 2-METHYL
SULPHONYL-4-AMINO-5-CYANO-6-(1’-N-PHENYL-3’-ARYL-PYRAZOL-4’-YL)-
PYRIMIDINES.
(A) Preparation of 2-Mercaptomethyl-4-amino-5-cyano-6-(1’-N-phenyl-
          3’-(p-methyl phenyl)-pyrazol -4’-yl) -1,6-dihydro pyrimidine  (IVc).
For preparation refer Part-I, Section-IV, Page No. 77.
(B) Preparation of 2-Methylsulphonyl-4-amino-5-cyano-6-(1’-N-phenyl-
            3’-(p-methyl phenyl)-pyrazol -4’-yl) pyrimidine (Vc).
2-mercaptomethyl-4-amino-5-cyano-6-(1’-N-phenyl-3’(p-methyl phe-
nyl)-pyrazol-4’-yl)-1,6-dihydro pyrimidine  (4.00 gm, 0.01M) was dissolved in
20ml of glacial acetic acid and add 12 ml of hydrogen peroxide  and then kept
for 48 hrs. at room temperature. The content was poured into ice cold water and
filtered. The product was isolated and crystallized from ethanol. Yield : 62%,
M.P. : 108°C, R f1
 : 0.55, R f2
 : 0.63 (Required : C, 61.38%; H, 4.21%; N, 19.53%
for C22H18N6O2S, Found : C, 61.33 %; H, 4.15%; N, 19.47%).
Similarly, other compounds (Va-h) were synthesized. The physical data are
recorded in Table No. 5.
(C) Antimicrobial activity of 2-Methylsulphonyl-4-amino-5-cyano-6-
(1’-N-phenyl-3’-aryl-pyrazol -4’-yl) pyrimidines (V a-h).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 43. The MIC values of test solution are recorded in Table No.
5a,5b,5c.
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PREPARATION AND BIOLOGICAL EVALUATION OF 2-[(2”,4”-DINITRO
PHENYL)THIO]-4-AMINO-5-CYANO-6-(1’-N-PHENYL-3’-ARYL-PYRAZOL-4’-
YL)-1,6-DIHYDRO PYRIMIDINES.
Due to enormous biodynamic activities47-106  of  pyrimidines and with a
view to have potent therapeutic agents, the synthesis o f  2-[ (2” ,4 ” -
dinitrophenyl)thio]-4-amino-5-cyano-6-(1’-N-phenyl-3’-aryl-pyrazol-4’-yl)-
1,6-dihydro pyrimidines(VIa-h) have been undertaken by the condensation of 2-
mercapto-4-amino-5-cyano-6-(1’-N-phenyl-3’-aryl-pyrazol-4’-yl)-1,6-dihydro









The constitution of the products (VIa-h) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (VIa-h) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) :  0 (control), 5, 10, 25, 50, 100, 200, 500  for their MIC (Minimum In-
hibitory Concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
  ( VIa-h )                                             R=Aryl
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  IR SPECTRAL STUDY OF 2-[(2”,4”-DINITRO PHENYL)-THIO]-4-AMINO-
  5-CYANO-6-(1’-N-PHENYL-3’-(p-METHOXY PHENYL)-PYRAZOL-4’-YL)-
  1,6- DIHYDRO PYRIMIDINE (VIb)
      Type
 Alkane
 CH3












 C=C + C=N and ring
skeletal  vibration
 C-H str.
 C-H i.p. def.
 C-H o.o.p. def.
 C-O-C str. (asym.)
 C-O-C str. (sym.)
 N-H str.
 N-H def.
 CºN  str.
 C=N  str.
 N -N  def.




















   2939.3
   2871.3
   1444.6
   1340.4
   1512.1
   1535.2
   3030.0
   1116.7
     810.0
   1232.4
   1056.9
    3367.5
    1610.5
    2225.7
    1577.7
    1637.4
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PMR SPECTRAL STUDY OF 2-[(2”,4”-DINITROPHENYL)-THIO]-4-AMINO-5-
CYANO-6-(1’-N-PHENYL-3’-(p-METHOXY PHENYL)-PYRAZOL-4’-YL)-1,6-
DIHYDRO PYRIMIDINE  (VIb)
       1
       2
       3
      4
  Signal
    No
    Signal position
      (d  ppm)
    Relative No.
     of Protons    Multiplicity       Inference
         3.895
      7.039-7.790
      8.386-8.763
     9.030
       3H
      12H
       4H




   singlet
 -OCH3(a)
 Ar-H(b)+Ar-H +NH2
 Ar-H(c)  +  Ar-H(d) +






































































































































































































































































(M +1) (M -1)
(M -1) (M -2)
(M +2)
(M +1)




































                                                           REACTION SCHEME
(VIa-h)    R=Aryl
   (Ia-h )
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 2-[(2”,4”-DINITRO
PHENYL)THIO]-4-AMINO-5-CYANO-6-(1’-N-PHENYL-3’-ARYL-PYRAZOL-4’-
YL)-1,6-DIHYDRO  PYRIMIDINES.
(A) Preparat ion of  2-Mercapto-4-amino-5-cyano-6-(1’ -N-phenyl-
           3 ’ - (p-methoxyphenyl)-pyrazol-4’-yl) -1,6-dihydro pyrimidine  (Ib)
For preparation refer part-I,section-I, page no.43.
(B) Preparation of 2-[(2”,4”-Dinitro phenyl)thio]-4-amino-5-cyano-6-(1’-
N-phenyl-3’-(p-methoxy phenyl)-pyrazol-4’-yl)-1,6-dihydro pyrimidine (VIb)
A mixture of 2-Mercapto-4-amino-5-cyano-6(1’-N-phenyl-3’-(p-methoxy
phenyl)-pyrazol-4’-yl)-1,6-di hydro pyrimidine  (4.02gm, 0.01 M),  and 2,4-dinitro
chloro benzene  (2.02 gm, 0.01 M) in ethanol(30 ml) and add 2 ml of 10% aque-
ous sodium hydroxide was heated under refluxed condition for  three hrs. The
product was isolated and crystallized from ethanol. Yield : 53%, M.P. : 173°C,
Rf1
 : 0.60, Rf2
 : 0.56 (Required : C, 57.04%; H, 3.52%; N, 19.72% for
C27H20N8O5S, Found :C, 56.98%; H, 3.46%; N, 19.67% )
Similarly, other compounds (VIa-h) were synthesized. The physical data
are recorded in Table No.6.
(C)    Antimicrobial activity of 2-[(2”,4”-Dinitro phenyl)thio]-4-amino-5-
           cyano-6-(1’-N-phenyl-3’-aryl pyrazol-4’-yl)-1,6-dihydro pyrimidines (VIa-h)
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 43. The MIC values of test solution are recorded in Table No.
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PREPARATION AND BIOLOGICAL EVALUATION OF 2-[(2”,4”-
DINITROPHENYL)-SULPHONYL]-4-AMINO-5-CYANO-6-(1’-N-PHENYL-3’-
ARYL-PYRAZOL-4’-YL) PYRIMIDINES.
In view of various biodynamic activities47-106 of  pyrimidines and in or-
der to have highly potent therapeutic agents, the synthesis of 2-[(2” ,4 ” -
dinitrophenyl) -sulphonyl]-4-amino-5-cyano-6-(1’-N-phenyl-3’-aryl-pyrazol-
4’-yl)-pyrimidines(VIIa-h) have been undertaken by the reaction of  2-[(2”,4”-
dinitrophenyl)  thio]-4-amino-5-cyano-6-(1’-N-phenyl-3’-aryl-pyrazol-4’-yl)-











The constitution of the products (VIIa-h ) have been delineated by elemen-
tal analyses, IR, PMR  and Mass spectral data.
The products (VIIa-h ) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) :  0 (control), 5, 10, 25, 50, 100, 200, 500  for their MIC (Minimum In-
hibitory  Concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
(VIIa-h )                                                     R=Aryl
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      Type
 Alkane
 CH3












 C=C + C=N and ring
skeletal  vibration
 C-H str.
 C-H i.p. def.
 C-H o.o.p. def.
 N-H str.
 N-H def.
 CºN  str.
 C=N  str.
 N -N  def.
 C -N str.
 S=O str. (asym.)





















   2923.9
   2871.8
   1442.7
   1377.3
   1490.3
   1564.2
   3064.7
   1099.3
     831.3
    3408.0
    1649.0
    2227.6
    1637.5
    1583.4
    1190.0
    1325.0
    1159.1
  IR SPECTRAL STUDY OF 2-[(2”,4”-DINITRO PHENYL)-SULPHONYL]-4-
  AMINO-5-CYANO-6-(1’- N-PHENYL-3’-(p-METHYL PHENYL)-PYRAZOL-4’-YL)-
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PMR SPECTRAL STUDY OF 2-[(2”,4”-DINITROPHENYL)-SULPHONYL]-4-
AMINO-5-CYANO-6-(1’-N-PHENYL-3’-(p-METHYLPHENYL)-PYRAZOL-4’-YL)
PYRIMIDINE  (VIIc)
       1
       2
       3
       4
       5
  Signal
    No
    Signal position
      (d  ppm)
    Relative No.
     of Protons    Multiplicity       Inference
         2.421
      7.298-7.325
      7.346-7.514
      7.798-7.823
      8.293
       3H
       2H
       8H
       2H
       1H
    singlet
   doublet
   multiplet
   doublet





























































































































































































































































































PREPARATION AND BIOLOGICAL EVALUATION OF 2-[(2”,4”-DINITRO-
PHENYL)-SULPHONYL]-4-AMINO-5-CYANO-6-(1’-N-PHENYL-3’-ARYL-
PYRAZOL-4’-YL) PYRIMIDINES.
(A) Preparation of 2-[(2”,4”-Dinitro phenyl) thio]-4-amino-5-cyano-6-(1’-
N-phenyl-3’-(p-methoxy phenyl)pyrazol-4’-yl)-1,6-dihydro pyrimidine (VIb)
For preparation refer part-I,section-VI, page no.99.
(B) Preparation of 2-[(2”,4”-Dinitro phenyl)-sulphonyl]-4-amino-5-
cyano-6-(1’-N-phenyl-3’-(p-methoxyphenyl)pyrazol-4’-yl)-1,6-dihydro
pyrimidine (VIIb)
A mixture of 2-[(2”,4”-Dinitro phenyl)thio]-4-amino-5-cyano-6-(1’-N-phe-
nyl-3’-(p-methoxyphenyl)-pyrazol-4’-yl)-1,6-dihydro pyrimidine. (5.68gm, 0.01 M),
was dissolved in 20ml of glacial acetic acid and add 12 ml of hydrogen perox-
ide and then kept for 48 hrs. at room temperature. The content was poured into
ice cold water and filtered. The product was isolated and crystallized from etha-
nol.  Yield : 59%, M.P. : 231°C, R f1
 : 0.64,  R f2
 : 0.53 (Required : C, 54.18%;
H, 3.01%; N, 18.73% for C 27H18N8O7S, Found : C, 54.12%; H, 2.95%; N,
18.67%
Similarly, other compounds (VIIa-h ) were synthesized. The physical data
are recorded in Table No7.
(C) Antimicrobial activity of 2-[(2”,4”-Dinitro phenyl)-sulphonyl]-
4-amino-5-cyano-6-(1’-N-phenyl-3’-(p-methoxyphenyl)pyrazol-4’-yl)-
1,6-dihydro pyrimidines (VIIa-h )
Antimicrobial activity testing was carried out as described in part-1, sec-
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PREPARATION AND BIOLOGICAL EVALUATION OF 2-[(2',4'-DINITRO
PHENYL)SULPHONYL]-4-AMINO-5-CYANO-6-ARYL-PYRIMIDINES
Due to enormous biodynamic activities47-106 of  pyrimidines and with a
view to have potent therapeutic agents, the synthesis of2-[(2',4'-dinitrophenyl)-
sulphonyl]-4-amino-5-cyano-6-aryl- pyrimidines (VIIIa-j) have been un-
dertaken by the condensation of 2-[(2',4'-dinitrophenyl)  thio]-4-amino-5-











The constitution of the products (VIIIa-j) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (VIIIa-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) :  0 (control), 5, 10, 25, 50, 100, 200, 500  for their MIC (Minimum In-
hibitory  Concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
( VIIIa-j )                                                            R=Aryl
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      Type
 Alkane
 CH3













 C=C + C=N and ring
skeletal  vibration
  C-H str.
  C-H i.p. def.
  C-H o.o.p. def.
  C-O-C str. (asym.)
  C-O-C str. (sym.)
  N-H str.
  N-H def.
  CºN  str.
  C=N  str.
  N -N  def.
  C -N str.
  S=O str. (asym.)























   2939.3
   2867.9
   1444.6
   1340.4
   1512.1
   1577.2
   3051.2
   1116.7
     840.9
   1232.4
   1056.9
   3367.5
   1598.9
   2225.7
   1610.4
   1637.4
   1153.4
   1340.0
   1178.4
  IR SPECTRAL STUDY OF 2-[(2’,4’-DINITRO PHENYL)-SULPHONYL]-4-
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PMR SPECTRAL STUDY OF 2-[(2’,4’-DINITROPHENYL)-SULPHONYL]-4-
AMINO-5-CYANO-6-(p-METHOXY PHENYL)PYRIMIDINE  (VIIIh)
       1
       2
       3
       4
       5
  Signal
    No
    Signal position
      (d  ppm)
    Relative No.
     of Protons    Multiplicity       Inference
         3.870
      7.011-7.246
      8.112-8.143
      9.123-9.132
      9.868
       3H
       4H
       1H
       1H
       1H
    singlet
  multiplet
double-dublet
   doublet
   singlet
         -OCH3(a)
          Ar-H
          Ar-H(b)
          Ar-H(c)





















































































































































































































































































                                                           REACTION SCHEME
     (VIIIa-j) R=Aryl
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 2-[(2',4'-DINITRO
PHENYL)-SULPHONYL ]-4-AMINO-5-CYANO-6-ARYL-PYRIMIDINES
(A)     Preparation of 2-[(2',4'-Dinitrophenyl) thio]-4-amino-5-cyano-6-
         (p-methoxyphenyl)-1,6-dihydro pyrimidine .
A mixture of 2-mercapto-4-amino-5-cyano-6-(p-methoxyphenyl)-1,6-
dihydro pyrimidine  (2.60 gm, 0.01 M) and 2,4-dinitro chlorobenzene  (2.02 gm,
0.01 M) in ethanol (30 ml) and add 2 ml of 10% aqueous sodium hydroxide
was heated under refluxed condition for three hrs. The content was poured into
ice cold water and filtered. The product was isolated and crystallized from etha-
nol. Yield : 65%, M.P. : 124°C, R f1
 : 0.64, R f2
 : 0.58 (Required : C, 50.70%; H,
3.29%; N, 19.72% for C18H14N 6O5S, Found : C, 50.65%; H, 3.25%; N,
19.66%).
(B)      Preparation of 2-[(2' ,4'-dinitrophenyl)-Sulphonyl]-4-amino-5-
           cyano-6-(p-methoxyphenyl) pyrimidine  (VIIIh)
A mixture of 2- [ (2 ' ,4 ' -D in i t rophenyl ) th io ] - 4-amino-5-cyano-6-
(p-methoxyphenyl)-1,6-dihydro pyrimidine  (4.26 gm, 0.01 M) was dissolved
in 20ml of glacial acetic acid and add 12 ml of hydrogen peroxide and then
kept for 48 hrs. at room temperature. The content was poured into ice cold water
and filtered. The product was isolated and crystallized from ethanol. Yield : 60%,
M.P. : 208°C, R f1
 : 0.58, R f2
 : 0.63 (Required : C, 47.37%; H, 2.63%; N, 18.42%
for C18H12N6O7S, Found : C, 47.32%; H, 2.57%; N, 18.36%)
Similarly, other compounds (VIIIa-j) were synthesized. The physical data
are recorded in Table No. 8.
(C) Antimicrobial activity of 2-[(2',4'-Dinitrophenyl) -Sulphonyl]-4-
          amino-5-cyano-6-aryl-1,6-dihydro pyrimidines (VIIIa-j).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 43. The MIC values of test solution are recorded in Table No.
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PART - II
STUDIES ON CARBOXAMIDO PYRIMIDINES
INTRODUCTION
Carboxamides are the substituted product of ammonia  and acid. The
characteristic group present in the simple carboxylic amide  is -CONH2. Many
natural products are amides, urea, diamides  of carbonic acid . Peptides and
proteins are the linear structures of cyclic polyamides. Alkaloids  of pepper,
piperine and chavicine  are N-substituted amides of unsaturated acid. N -
isobutyl amides  of certain highly unsaturated aliphatic acids  occur in plants
and show insecticidal activity159. Amides derived from polyacetylenic acids
have been  isolated from certain fungi160. Herbicidal and insecticidal activi-
ties161,162 are well documented in literature.
SYNTHETIC METHODS OF CARBOXAMIDO PYRIMIDINE
Several methods for the preparation of Carboxamides have been
described as under :
(a) By the reaction of 2-amino-4,6-dimehtyl pyrimidine and 2,5-dim
ethylpyrrole with CISO2CNO led to the formation of carboxamido pyrimidine
163.
(b) By the acylation of the amino acid with p-chlorobenzoylchloride , then
converting the acid  into the cyclohexylamide via  lactam, lactone or
anhydride to yield 2,4-dihydroxy-5-(p-chlorobenzamido)-6-cyclo hexyl
aminocarbonyl) pyrimidine164.
(c) By the cyclization of 2-cyano-3-aryl acrylamide  with thiourea led to
the formation of carboxamido pyrimidines165.
(d) By the condensation of 2-thiobarbituric acid  with phenyl isocyanate  led
to the formation of carboxamido pyrimidines166.
(e) By the reaction of 2-trifluoro methyl-5-methylsulphonyl-1,3,4-triazole
and 4-hydroxyaniline  with hexahydro-2,4,6-trioxo-5-pyrimidine
carboxylate led to the formation of carboxamido pyrimidines167.
(f) By the cyclocondensation of 1,2-dibromo-1-carboxyl-2-ethanal with
chlorinated product aminated by p-fluoroaniline which on further
oxidation led to the formation of carboxamido pyrimidines168.
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THERAPEUTIC IMPORTANCE OF CARBOXAMIDO PYRIMIDINES
Carboxamido pyrimidines  have been widely used as pharmacologically
useful entities. Several biological activities have been reported as under.
(a) Antipyretic169 (b) Analgesic170
(c) Anticancer171 (d) Anticonvulsant172,173
(e) Anthelmintic174 (f) Hypoglycemics175
(g) Antiallergic176 (h) Antiulcer177
(i) Tranquilizer178 (j) Cardiovascular179,180
(k) CNS-depressant181 (l) Diuretic182
(m) Psychotropic183 (n) Antimicrobial184-190
(o) Antagonist191-193 (p) Antithrombic194
(q) Antiamoebic195 (r) Antiarrhythmic196
(s) Antitumor197
H.E. Weidermann et al.,198 have synthesized pyrimidine carboxamides
(42) which reduces blood sugar in rats by 19% at 5mg/kg and U. Herzog et al.,199















          (42)                                                                              (43)
                                                                   R1=H/napthyl/alkyl;R2,R3=H/alkyl;
                                                                  NR2R3=heterocyclic;R4=napthyl/alkyl;
P.F. Juby et al.,200 have prepared pyrimidine-5(N)-(1H-tetrazol-5-yl)
carboxamides (44) which showed antiallergic activity and K.Atwal et al.,201
















     (44)     R=Tetrazolyl
B. Ojo et al., 202 have synthesized 1,4,5,6-tetrahydro pyrimidine
5-carboxamides  (46, 47) and their salts, having binding affinities and agonist











H. Hisamichi et al.,203 have synthesized 5-carboxamido pyrimidine








X=O/S/NR1/CO/CONR1; Y=lower alkylene-optionally subs. by OR or NHR1; Z=O,
NR2, A=H, B=Optically subs. aryl / heteroaryl; R1,R2= H
F. Kobayashi et al.,204 have prepared (1,6-dihydro-6-oxo-1-pyrimidinyl-
1-pyridinyl) acetamide derivatives  (49) as antibody production inhibitors are
useful as preventives or remedies for bronchial asthma, allergic dermatitis etc.
U. Pfaar et al.,205 have prepared carboxamido pyrimidine  derivatives
(50) and reported for their antitumor activity.
R1,R3=H/halogen/aryl;














In view of procuring highly potent biodynamic agents and after reviewing
literature survey on carboxamido pyrimidines for their various methods of
synthesis and different biological activities, synthesis of carboxamido pyrimidines
have been undertaken which can be summarized in the following sections as
under.
SECTION – I :  PREPARATION AND BIOLOGICAL EVALUATION OF  2-
                          MERCAPTO- 4-AMINO-5-CARBOXAMIDO-6-(1’-N-PHENYL-3’-









    R1=OH;  R 2=H/alkyl/hydroxyalkyl;  R=NR3R4/CR3R4/OR3R4;
    R3R4=alkylene/oxaalkylene/azaalkylene
(50)
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SECTION – II :  PREPARATION AND BIOLOGICAL EVALUATION OF  2-
                           SULPHONYL-[(2’,4’-DINITRO PHENYL)-THIO- 4-AMINO-5-
                           CARBOXAMIDO-6-ARYL PYRIMIDINES.
SECTION – III :  PREPARATION AND BIOLOGICAL EVALUATION OF 2-
                            MERCAPTO- 4-AMINO-5-CARBOXAMIDO-6-(1’-N-PHENYL-
                            3’-ARYL PYRAZOL-4’-YL)-1,6-DIHYDRO PYRIMIDINES.
SECTION – IV :  PREPARATION AND BIOLOGICAL EVALUATION OF  2-
                             HYDROXY- 4-AMINO-5-CARBOXAMIDO-6-(1’-N-PHENYL-
                             3’-ARYL PYRAZOL-4’-YL)-1,6-DIHYDRO PYRIMIDINES.
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SECTION - I
PREPARATION AND BIOLOGICAL EVALUATION OF 2-MERCAPTO-4-
AMINO-5-CARBOXAMIDO-6-(1’-N-PHENYL-3’-ARYL-PYRAZOL-4’-YL)
PYRIMIDINES
Looking to the biodynamic profile 169-205 and the other properties159-162
of carboxamido pyrimidines  and in view to have potent therapeutic agents, the
synthesis of 2-mercapto-4-amino-5-carboxamido-6-(1’-N-phenyl-3’-aryl-
pyrazol-4’-yl)- pyrimidines  (IXa-h) have been   undertaken by the reaction of 2-
mercapto-4-amino-5-cyano-6-(1’-N-phenyl-3’-aryl-pyrazol-4’-yl)-1,6-dihydro-









The constitution of the products (IXa-h) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (IXa-h) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) :  0 (control), 5, 10, 25, 50, 100, 200, 500  for their MIC (Minimum In-
hibitory  Concentration) values. The biological activities of the synthesized com-
pounds  were compared with standard drugs.
( IXa-h )                                  R=Aryl
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      Type
 Alkane
 CH3











 C=C + C=N and ring
skeletal  vibration
 C-H str.
 C-H i.p. def.




N -N  def.
C -N str.





















   2921.9
   2862.2
   1454.2
   1365.5
   1519.8
   1571.9
   3062.7
   1112.8
     825.5
     3433.1
    1598.9
    1618.2
    1637.4
    1218.9
    3325.1
    1672.2
  IR SPECTRAL STUDY OF 2-MERCAPTO-4-AMINO-5-CARBOXAMIDO-6-
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PMR SPECTRAL STUDY OF 2-MERCAPTO-4-AMINO-5-CARBOXAMIDO-
6-(1’-N-PHENYL-3’-(p-METHYLPHENYL)-PYRAZOL-4’-YL) PYRIMIDINE (IXc)
       1
       2
       3
       4
       5
  Signal
    No
    Signal position
      (d  ppm)
    Relative No.
     of Protons    Multiplicity       Inference
         2.448
      7.325-7.510
      7.539-7.566
      7.446-7.772
      8.250
       3H
       7H
       2H
       2H
       1H
    singlet
    multiplet
   doublet
   doublet
   singlet
 -CH3(a)
























































































































































































































                                                           REACTION SCHEME
  (IXa-h) R=Aryl
    (Ia-h )
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 2-MERCAPTO-4-
A M I N O - 5-CARBOXAMIDO-6-(1’-N-PHENYL-3’-ARYL-PYRAZOL-4’-YL)
PYRIMIDINES.
(A) Preparation of 2-Mercapto-4-amino-5-cyano-6-(1’-N-phenyl-3’-
(p-methyl phenyl)-pyrazol-4’-yl) -1,6-dihydro pyrimidine(Ic).
For preparation refer part-I,section-I, page no.43.
(B) Preparation of 2-Mercapto-4-amino-5-carboxamido-6-(1’-N-phenyl-3’-
(p-methyl phenyl)-pyrazol-4’-yl) pyrimidine(IXc).
2-Mercapto-4-amino-5-cyano-6-(1’-N-phenyl-3’- (p-methyl phenyl)pyrazol-
4’-yl)-1,6-dihydro pyrimidine(3.86 gm, 0.01M) was dissolved in concentrated
sulphuric acid (20ml) below 5 oC and kept for 48 hrs. at room temperature. The
content was poured into ice cold water and filtered. The product was isolated and
crystallized from ethanol. Yield : 50%, M.P. : 212°C, R f1
 : 0.45, R f2
 : 0.54(Re-
quired :C, 62.69%; H, 4.48%; N, 20.89% for C21H 18N6OS, Found : C,
62.64%; H, 4.43%; N, 20.83%)
Similarly, other compounds (IXa-h) were synthesized. The physical data
are recorded in Table No. 9
(C) Ant imicrobia l  act iv i ty  of  2-Mercapto-4-amino-5-carboxamido-6-(1’-
         N-phenyl-3’-aryl-pyrazol-4’-yl) pyrimidines(IXa-h).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 43. The MIC values of test solution are recorded in Table No.
9a,9b &9c.
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SECTION - II
PREPARATION AND BIOLOGICAL EVALUATION OF 2-[(2',4'-DINITRO
P H E N Y L ) - S U L P H O N Y L ] - 4 - A M I N O - 5 - C A R B O X A M I D O - 6 - A R Y L -
PYRIMIDINES.
Due to enormous biodynamic activities169-205 and other properties159-162
of  pyrimidines  and with a view to have potent therapeutic agents, the synthesis
of2-[(2',4'- dinitrophenyl) -sulphonyl]-4-amino-5-carboxamido-6-aryl-
pyrimidines(Xa-j) have been undertaken by the condensation of 2-[(2',4'-













The constitution of the products (Xa-j) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (Xa-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) :  0 (control), 5, 10, 25, 50, 100, 200, 500  for their MIC (Minimum In-
hibitory concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
(Xa-j )                                                           R=Aryl
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        Type
     Alkane
    CH3
   Aromatic and
   Pyrimidine
    moiety
   Amine(Primary)
   Pyrazole
    Amide
   Ether
   Sulphonyl Aryl













N -N  def
C -N str





























   2929.7
   2854.5
   1446.5
   1379.0
   1506.3
   1541.0
   3049.2
   1095.5
     827.4
   3433.1
   1579.6
   1602.7
   1641.3
   1199.6
   3371.3
   1689.5
   1280.6
   1055.0
   1357.8
   1163.0
  IR SPECTRAL STUDY OF 2-[(2’,4’-DINITRO PHENYL)-SULPHONYL]-












































    374
     ,,
     ,,
     ,,
    375
     ,,
     ,,
     ,,
     ,,
    376
      ,,
      ,,
      ,,
    374
      ,,
    376
      ,,
      ,,
      ,,
Studies  on carboxamido pyrimidines 150
PMR SPECTRAL STUDY OF 2-[(2’,4’-DINITROPHENYL)-SULPHONYL]-4-
AMINO-5-CARBOXAMIDO-6-(p-METHOXY PHENYL)PYRIMIDINE  (Xh)
       1
       2
       3
       4
       5
  Signal
    No
    Signal position
      (d  ppm)
    Relative No.
     of Protons    Multiplicity       Inference
        3.871
      7.007-7.240
      8.120-8.151
      9.146
      9.872
       3H
       4H
       1H
       1H
       1H
    singlet
    multiplet
 double doublet
   doublet
   singlet
        -OCH3(a)
        Ar-H
        Ar-H(b)
        Ar-H(c)



























































































































































































































































































                                                           REACTION SCHEME
(Xa-j)           R=Aryl
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 2-[(2',4'-DINITRO PHE-
NYL)-SULPHONYL]-4-AMINO-5-CARBOXAMIDO-6-ARYL PYRIMIDINES
(A)     Preparation of 2-[(2',4'-dinitrophenyl) thio]-4-amino-5- carboxamido-
          6- (p-methoxyphenyl) pyrimidine.
A mixture of 2-Mercapto-4-amino-5-carboxamido-6-(p-methoxyphenyl)
pyrimidine (2.76gm, 0.01 M), and 2,4-dinitro chloro benzene  (2.02 gm, 0.01 M) in
ethanol(30 ml) and add 2 ml of 10% aqueous sodium hydroxide  was heated
under refluxed condition for  three hrs. The product was isolated and crystallized
from ethanol. Yield : 63%, M.P. : 126°C, Rf1
 : 0.48, R f2
 : 0.56 (Required : C,
52.17%; H, 4.35%; N, 20.29% for C12H12N4O2S, Found :C, 52.10%; H,
4.28%; N, 20.23%.)
(B)      Preparation of 2-[(2' ,4'-dinitrophenyl)-Sulphonyl]-4-amino-5-
           carboxamido -6-(p-methoxyphenyl)  pyrimidine  (Xh).
2 - [ ( 2 ' , 4 ' - di n i t r o p h e n y l ) t h i o ] - 4 - a m i n o - 5 - ca r b o x a m i d o - 6 -
(p-methoxyphenyl) pyrimidine  (4.42 gm, 0.01 M) was dissolved in 20ml of gla-
cial acetic acid and add 12 ml of hydrogen peroxide  and then kept for 48 hrs. at
room temperature. The content was poured into ice cold water and filtered. The
product was isolated and crystallized from ethanol. Yield : 62%, M.P. : 189°C,
Rf 1
 : 0.66,Rf2
 : 0.60 (Required : C, 48.87%; H, 3.17%; N, 17.72% for
C18H14N6O6S, Found : C, 48.82 %; H, 3.11%; N, 17.65%).
Similarly, other compounds (Xa-j) were synthesized. The physical data are
recorded in Table No. 10.
(C) Antimicrobial  act ivi ty of  2-[(2' ,4' -dinitrophenyl)-Sulphonyl]-
          4-amino-5-carboxamido -6-aryl  pyrimidines  (Xa-j)
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 43. The MIC values of test solution are recorded in Table No.
10a, 10b & 10c.
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SECTION - III
PREPARATION AND BIOLOGICAL EVALUATION OF 2-MERCAPTO-4-
AMINO-5-CARBOXAMIDO-6-(1’-N-PHENYL-3’-ARYL-PYRAZOL-4’-YL)-1,6-
DIHYDRO PYRIMIDINES
Looking to the biodynamic profile 169-205 and the other properties159-162
of carboxamido pyrimidines  and in view to have potent therapeutic agents,the
synthesis of 2-mercapto-4-amino-5-carboxamido-6-(1’-N-phenyl-3’-aryl-
pyrazol-4’-yl)-1,6-dihydro pyrimidines (XIa-h) have been undertaken by the con-
densat ion of  di f ferent 3-(1’-N-phenyl-3’-aryl pyrazol-4’-yl)-2-cyano









The constitution of the products (XIa-h) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (XIa-h) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) :  0 (control), 5, 10, 25, 50, 100, 200, 500  for their MIC (Minimum In-
hibitory  Concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
(XIa-h  )                               R=Aryl
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  IR SPECTRAL STUDY OF 2-MERCAPTO-4-AMINO-5-CARBOXAMIDO-6-(1’-N -
  PHENYL-3’-(p-METHYL PHENYL)-PYRAZOL-4’-YL)-1,6-DIHYDRO PYRIMIDINE (XIc)














 C=C + C=N and ring
skeletal  vibration
 C-H str.
 C-H i.p. def.
 C-H o.o.p. def.
 N-H str.
 N-H def.
 C=N  str.
 N -N  def.
C -N str.




   2923.9
   2852.5
   1444.6
   1367.4
   1490.9
   1552.6
   3064.7
   1109.0
     846.7
   3330.8
   1610.5
   1631.7
   1591.2
   1172.6
   3406.1
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PMR SPECTRAL STUDY OF 2-MERCAPTO-4-AMINO-5-CARBOXAMIDO-
6-(1’-N-PHENYL-3’-(p-METHYL PHENYL)-PYRAZOL-4’-YL)-1,6-DIHYDRO
PYRIMIDINE  (XIc)
       1
       2
       3
       4
       5
       6
       7
  Signal
    No
    Signal position
      (d  ppm)
    Relative No.
     of Protons    Multiplicity       Inference
        2.454
       7.002
      7.370-7.396
      7.480-7.536
      7.744-7.769
         8.368
         9.010
       3H
       1H
       2H
       5H
       2H
       1H
       1H
    singlet
    singlet
   doublet
   multiplet
   doublet
   singlet







































































































































































































































                                                           REACTION SCHEME
  (XIa-h) R=Aryl
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 2-MERCAPTO-4-
AMINO-5-CARBOXAMIDO-6-(1’-N-PHENYL-3’-ARYL-PYRAZOL-4’-YL)-1,6-
DIHYDRO PYRIMIDINES(XIa-h)
(A) Preparation of 3-(1’-N-phenyl-3’-(p-methyl phenyl)-pyrazol-4’-yl) -2-
cyano acryl amide (1c)
To the mixture of 1-N-phenyl-3-(p-methyl phenyl)-pyrazol-4-
carboxaldehyde (2.62 gm, 0.01 M) and cyano acetamide  (0.84 gm, 0.01 M) in
DMF (30 ml), 8 ml of glacial acetic acid was added and the reaction mixture was
stirred for 48 hrs. at room temperature . The  content was poured into ice cold
water and filtered. The  product was isolated and crystallized from ethanol.
Yield :64%, M.P. :138°C, R f1
 : 0.58, R f2 
:0.47 (Required : C, 58.43%; H, 3.48%;
N, 14.61% for C 14H10N3O2Cl,    Found : C, 58.39%; H, 3.43%; N,  14.56%).
Similarly, other compounds (1a-h) were synthesized. The physical data
are recorded in Table No. 11(I).
(B) Preparation of 2-Mercapto-4-amino-5-carboxamido-6-(1’-N-phenyl-3’-
(p-methyl phenyl)-pyrazol-4’-yl) 1,6-dihydro pyrimidine(XIc).
           A mixture of 3-(1’-N-phenylL-3’-(p-methyl phenyl)-pyrazol-4’-yl) -2-cy-
ano acryl amide  (3.28gm, 0.01M) and thiourea (0.76 gm, 0.01M) in DMF (20
ml) was heated in  an oil-bath at 130 oC for 8 hrs. in presence of potassium
carbonate . The content was poured into ice cold water and neutralized with di-
luted hydrochloric acid and filtered. The product was isolated and crystallized
from DMF . Yield : 62%, M.P. : 129°C, Rf1
 : 0.62, Rf2 
:0.56 (Required : C,
62.38%; H, 4.95%; N, 20.79 % for C21H20N6OS; Found :C, 62.32%; H, 4.89%;
N, 20.74 % )
Similarly, other compounds (XIa-h) were synthesized. The physical data
are recorded in Table No.11.
(C) Ant imicrobia l  act iv i ty  of  2-Mercapto-4-amino-5-carboxamido-6-(1’-
          N-phenyl-3’-aryl-pyrazol-4’-yl)-1,6-dihydro pyrimidines(XIa-h).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 43. The MIC values of test solution are recorded in Table No.
11a,11b &11c
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SECTION - IV
PREPARATION AND BIOLOGICAL EVALUATION OF 2-HYDROXY-4-AMINO-
5-CARBOXAMIDO-6- (1 ’ -N-PHENYL-3 ’ -ARYL-PYRAZOL-4 ’ -YL) -1 ,6-
DIHYDRO PYRIMIDINES
Looking to the biodynamic profile 169-205 and the other properties159-162
of carboxamido pyrimidines  and in view to have potent therapeutic agents, the
synthesis of 2-hydroxy-4-amino-5-carboxamido-6-(1’-N-phenyl-3’-aryl-
pyrazol-4’-yl)- 1,6-dihydro pyrimidines  (XIIa-h ) have been   undertaken by the
condensation of different 3-(1’-N-phenyl-3’-aryl pyrazol-4’-yl)-2-cyano









The constitution of the products (XIIa-h ) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (XIIa-h ) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) :  0 (control), 5, 10, 25, 50, 100, 200, 500  for their MIC (Minimum In-
hibitory  Concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
(XIIa-h  )                         R=Aryl
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      Type
 Alkane
 CH3













 C=C + C=N and ring
skeletal  vibration
 C-H str.
 C-H i.p. def.
 C-H o.o.p. def.
 C-O-C str. (asym.)
 C-O-C str. (sym.)
 N-H str.
 N-H def.
 -OH  str.
 C=N  str.
 N -N  def.
 C -N str.
 N -H  str.























   2916.2
   2850.0
   1461.9
   1369.4
   1475.4
   1550.7
   3060.8
   1110.9
     825.5
   1259.4
   1058.7
   3328.9
   1583.4
   3444.6
   1639.4
   1575.7
   1197.7
   3417.6
   1670.2
  IR SPECTRAL STUDY OF 2-HYDROXY-4-AMINO-5-CARBOXAMIDO-6-
  (1’- N- PHENYL-3’-(p-METHOXY PHENYL)-PYRAZOL-4’-YL)-1,6-DIHYDRO
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PMR SPECTRAL  STUDY OF 2-HYDROXY-4-AMINO-5-CARBOXAMIDO-6-
(1’-N-PHENYL-3’-(p-METHOXY PHENYL)-PYRAZOL-4’-YL)-1,6-DIHYDRO
PYRIMIDINE  (XIIb)
       1
       2
       3
       4
       5
       6
  Signal
    No
    Signal position
      (d  ppm)
    Relative No.
     of Protons    Multiplicity       Inference
        3.958
      7.129-7.157
      7.491-7.519
      7.561-7.613
        7.879
        8.993
       3H
       2H
       2H
       5H
       1H
       1H
    singlet
   doublet
   doublet
   multiplet
   singlet

















































































































































































































































                                                           REACTION SCHEME
   (XIIa-h ) R=Aryl
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 2-HYDROXY-4-AMINO-
5-CARBOXAMIDO-6- (1 ’ -N-PHENYL-3 ’ -ARYL-PYRAZOL-4 ’ -YL) -1 ,6-
DIHYDRO PYRIMIDINES
(A) Preparation of 3-(1’-N-phenylL-3’-(p-methoxy phenyl)-pyrazol-4’-yl) -
2-cyano acryl amide (1b)
For preparation refer part-II, section-III page no.165.
(B) Preparation of 2-Hydroxy-4-amino-5-carboxamido-6-(1’-N-phenyl-3’-
(p-methoxy phenyl)-pyrazol-4’-yl)-1,6-dihydro pyrimidine(XIIb).
           A mixture of 3-(1’-N-phenylL-3’-(p-methoxy phenyl pyrazol-4’-yl) -2-cy-
ano acryl amide  (3.44, 0.01M) and urea (0.6 gm, 0.01M) in DMF (20 ml) was
heated in  an oil-bath at 130 oC for 8 hrs. in presence of potassium carbonate .
The content was poured into ice cold water and neutralized with dilute hydro-
chloric acid and filtered. The product was isolated and crystallized from DMF .
Yield : 66%, M.P. : 134°C, Rf1 
:0.64, Rf2 
:0.57 (Required : C, 62.38%; H,
4.95%; N, 20.79 % for C 21H20N6O3; Found :C, 62.32%; H, 4.90%; N, 20.73)
Similarly, other compounds (XIIa-h ) were synthesized. The physical data
are recorded in Table No.12.
(C) Ant imicrobia l  act iv i ty  o f  2-Hydroxy-4-amino-5-carboxamido-6-(1’-
            N-phenyl-3’-aryl-pyrazol-4’-yl)-1,6-dihydro pyrimidines(XIIa-h ).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 43. The MIC values of test solution are recorded in Table No.
12a,12b & 12c.
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PART - III
STUDIES ON PYRIMIDINYL SULPHONAMIDES
INTRODUCTION
General formula of sulphonamides is -R-SO2-N-R’-R”. In sulphonamide groups
R,R’,R” can be hydrogen/ alkyl/ aryl/ hetero cyclic moiety .The initial discovery
of  the sulphonamides  was largely the result of serendipity. At the turn of the
century a wide variety  of azo dyes were in use and continuous efforts were beiging
made to improve the properties of these very useful compounds.It became popu-
lar to introduce the sulphonamide  group (51), which often gave the dyes extra
light stability, greater  water solubility  during application and a greater fixation to
certain fibres, particularly proteins such as wool. Of note were observations  such
as that made in 1932 that  the dye prontosil  (52) possessed  effective bacteri-
cidal properties  in vivo in small animals, for example the protection of mice
against streptococcal infection206 . This observation stimulated further studies
and shortly afterwards, in 1933, prontosil was used clinically in case of
staphylococcalsept icaemia.207  .
                  (51)
 R1 =Aryl or Heteroaryl group
 R2 =H, Alkyl, Aryl or Acyl group
During clinical studies it was confirmed that, where as prontocil was ac-
tive in vivo  assays proved ineffective. Attempts to modify the molecule showed
that variations in the nonsulphonamide  contaning portion of the azo dye had
little effect on in vivo  potency, only varying  degrees of consequence,different
potencies and ranges of activity beging observed.208 The subsequent finding
that prontosil was metabolized in vivo to give sulfanilamide (53). Rapid progress
in the clinical use of the latter and a range of related compounds became pos-
sible, aided by  the facts that sulfanilamide  was relatively easy and cheap to
manufacture and that since it was a well-known compounds, first prepared in
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              (53)                                          (54)
The sulphonamides , predating the penicillins , were thus the first group
of chemical compounds to be widely used as specific antibacterial agents.The
aliphatic sulphonamides  have not yet become important.Development of the
sulphonamide  led for the first time to the design evaluated clinical trials and
these in turn,resulted in important obversations on their side effects.Some of these
proved to give unexpected benefits eventually harnessed as new drug leads and
the application of various sulphonamides  derivatives in other important chemo-
therapeutic  areas,such as their use as diuret ics 210 , as oral ly act ive
antidiabetics211. Alongside the clinical studies, fundamental work on the mode
of action of the sulphonamides  commenced. The first clue on this was the ob-
servation by woods212 that the in vitro antibacterial action of the sulphonamides
could be reversed by addition od P-aminobenzoic acid .(55) This observation
suggested that the sulphonamides  acted as a competitive antagonist to the natu-
rally occurring PABA, known to be an essential growth factor for some microor-
ganisms, i.e that they are acting as antimetabolites. The concept of antimetabo-
lites developed by Fildes213 and has subsequently been applied to several other
areas of chemotherapy, notably in the nucleotide area.The early interest in the
sulphonamides  has been maintained to the present and the studies on seperating
out the beneficial side effects from the antibacterial properties have helped to
established methods for developing new leads from drugs as well as protocols
for toxicological studies. Finally, because of their relatively simple structure many
variations and analogues have been synthesized and these in turn have helped to
established the principles for optimizing drug design. Aromatic and heterocy-
clic sulphonamides  have achieved great commercial significance as their ap-
plication shown in the chemistry of sulphonamides  due to their use as antibacte-
rial, anticancer, antimalarial, antifungal, antiplasmodic, anticonvulsant, herbicidal,













                                                           (55)
CHEMICAL STRUCTURE OF THE SULPHONAMIDE GROUP
The availability of many crystalline derivatives of sulphonamides drugs
has given scope for several structural studies. The sulphonamide  group is
strongly electron attracting, leading to a high electron density on the sulfone oxygen
atoms and enhanching the acidity of the proton attached to nitrogen; N-
unsubstituted or mono substituted sulphonamides  behave as acids and readily
forms salts.Structurally the atoms linked to the central hexavalent sulfur atoms
are arranged tetrahedrally, as exemplified by the structures of the drugs hydro-
chlorothiazide (56)214 and torasemide  (57)215 which behave as diuretics,216
and sulthiame(58)217.The pKa values of sulphonamides  bearing a N-H bond
are generally in the range 4-9. Because of this the simple N-unsubstituted group
has often been compared to a carbonyl group,i.e a carbonyl isostere;the struc-
ture of sulphonamide(53) and (55) are very similar. Thus in the mejority of bio-
logical situations  the sulphonamides  are likely to be present as salts, although
for transport through membranes etc.,the unionized form is likely to be more eas-
ily transported,hence the pKa value is important in helping to determine the pen-


























                     (56)                                          (57)                                       (58)
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In sulphonamide  in which the nitrogen is further conjugated, such as
sulphaguanidine  (59)218 and  sulfapyridine ,219 the doubly bonded nitrogen
is the prefered tautomer. 220 Finally, in any intermolecular interactions account
must be given of the large dipole moment associated with sulphonamide  group
and surface charges,particularly those placed on the oxygen atoms.During at-
tempts to find active variations in the sulphonamide  structure it was foundthat
some diaryl sulfones also acted as antagonists of PABA  , for example the agent
dapson(60),221 which is still particularly useful in mycobacterial infections such
as leprosy.222 Structure-activity studies have demonstrated that these bind in a
similar manner to sulphonamides , substituents reinforcing negative charge on














SYNTHETIC METHODS OF SULPHONAMIDES
T h e  s y n t h e s i s  o f  s u l p h o n a m i d e s  h a v e  b e e n  r e p o r t e d  i n  t h e
l i terature223-224.
THERAPEUTIC IMPORTANCE OF  SULPHONAMIDES  DERIVATIVES
The sulphonamides  inhabit growing bacterial organisms.Considerable re-
search has been undertaken to extend the activity and   reduce toxicity of sulpha
drugs. Monogram and review225,226 surveying  various aspects of sulpha drugs
have been published. The sulphonamides  have been found to possess follow-
ing types of activity.
(a) Antihypertensive227 (b) Diuretic228-230
(c) Anticonvulsant231 (d) Antitumor232,233
(e) Herbicidal234,235 (f) Antiviral236
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(g) Antimalarial237 (h) Antimicrobial238-244
(i) Hypoglycemic245,246 (j) Cardiovascular247
(k) Hypotensive 248,249 (l) Anti conversant250
(m) AntiHIV activity251,252 (n) Antineoplastic activity253
(o) Antidiabetic activity254 (p) Aspartyl protease inhibitor255
(q) Mycobacterial agents256-259
OTHER CHEMOTHERAPEUTIC APPLICATION OF SULPHONAMIDES
Clinical observations on the earlier sulphonamides  showed that some
members had diuretic properties . The earlier sulphonamides  , particularly those
not having substitutents on the amide nitrogen,were shown  not to behave sodium
channel blocking agents such as triamterene (61) and amiloride (62) or chloride
channel blocking agents such as furosemide(63).
The sulphonamide methazolamide  (64) is particularly useful in the treat-












There is one other area where sulphonamide  derivatives have found clini-
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Recently,  H. Peyman et al.,256 have reported aryl sulphonamides   as
vitronectin receptor antagonists. F. Walter et al., B. Volker et al and.,Y. Isao et










STRUCTURE-ACTIVITY STUDIES ON SULPHONAMIDES
In order to unravel this complex set of parameters the problem is often divided
into parts: an examination of the efficacy of a potential drug in cell free system,
followed by studies on intact cell and then studies in animal and finally, clinical
studies in man. An important aim of studies on structure-activity relationship
(SAR) is to try to establish quantitative expressions (QSAR) relating chemical
structure to physicochemical properties of a group of drugs.The overall relation-
ship between dosing and effect may be devided in to three separate steps,the
pharmaceutical,pharmacokinetic and pharmacodynamic processes. In general
two types of physicochemical conditions are necessary for biological action:(1)
Chemical properties necessary to induce a physicochemical or chemical reac-
tion at the receptor site; and (2) physicochemical properties which determine the
pharmacokinetics of the drug.i.e absorption,distribution,metabolism,binding to
nonspecific binding sites and excretion with respect to the biological system involved.
(66)
(67)
The sulphonamides  used contain the sulphonylurea function, such as tolb-
utamide (65) and glipizide (66).Studies on these agents show that they do not pri-
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In view of procuring highly potent biodynamic agents and after reviewing
literature survey on sulphonamides  for their various method of synthesis and
different pharmacological activities, synthesis of pyrimidinyl sulphonamides
have been undertaken which can be summarized as under.
SECTION - I :  P R E P A R A T I O N  A N D  B I O L O G I C A L  E V A L U A T I O N  O F -
                        2-HYDROXY-4-(p-ACETAMIDOPHENYL SULPHONYLAMINO)-
    5-CARBOXMIDO-6-ARYL PYRIMIDINES.
SECTION - II :   PREPARATION AND BIOLOGICAL EVALUATION OF 2-
                          HYDROXY-4-(P-AMINOPHENYL SULPHONYLAMINO)-
      5-CARBOXMIDO-6-ARYL PYRIMIDINES.
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SECTION - I
PREPARATION AND BIOLOGICAL EVALUATION OF 2-HYDROXY-4-(p-
ACETAMIDOPHENYL SULPHONYLAMINO)-5-CARBOXAMIDO-6-ARYL
PYRIMIDINES
Keeping in view the interesting properties206-225and pharmacological
activities226-259 sulphonamides , it has been revealed that sulphonamides
are valuable drugs for various diseases and for viral diseases. These observa-
tion led us to synthesis of some novel 2-hydroxy-4-(p-acetamidophenyl
sulphonylamino)-5-carboxamido-6-aryl pyrimidines  (XIIIa-j) by condensation
of 2-hydroxy-4-amino-5-carboxamido-6-aryl pyrimidines with p-acetamido-
phenyl sulphonylchloride.
The constitution of the products (XIIIa-j) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (XIIIa-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500  for their MIC (Minimum In-
hibitory  Concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
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     Type             Vibration Mode             Frequency in cm-1             Reference.
                   Observed       Reported
   IR  SPECTRAL  STUDYOF 2-HYDROXY-4-(p-ACETAMIDO PHENYL
  S U L P H O N Y L  A M I N O ) -5 -CARBOXAMIDO-6 - (p- C H L O R O P H E N Y L )






    Hydroxy








C=C + C=N and ring
skeletal vibration
  C-H str.
  C-H i.p. def.
  C-H o.o.p. def.




 S=O str. (asym)
 S=O str. (sym)
 C=N  str.
 N -N  def.
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PMR SPECTRAL  STUDY OF 2-HYDROXY-4-(p-ACETAMIDO PHENYL
SULPHONYL AMINO)-5-CARBOXAMIDO-6-(p-CHLORO PHENYL ) PYRIMI-
DINE  (XIIIh)
       1
       2
       3
       4
       5
  Signal
    No
    Signal position
      (d  ppm)
    Relative No.
     of Protons    Multiplicity       Inference
        2.474
      7.358-7.385
      7.525-7.554
      7.825-7.852
      8.359-8.388
       3H
       2H
       2H
       2H
       2H
    singlet
   doublet
   doublet
   doublet
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    (XIIIa-j)        R=Aryl
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 2-HYDROXY-4-(p-
ACETAMIDOPHENYL SULPHONYLAMINO)-5-CARBOXAMIDO-6-ARYL
PYRIMIDINES
(A) Preparation of 2-Hydroxy-4-amino-5-carboxamido-6-(p-chloro
          phenyl) pyrimidine.
2-Hydroxy-4-amino-5-cyano-6-(p-chlorophenyl)-1,6-dihydro  pyri-
midine (2.48 gm, 0.01 M) was dissolved in concentrated sulphuric acid (20ml)
below 5 oC and kept for 48 hrs. at room temperature. The content was poured
into ice cold water and filtered. The product was isolated and crystallized
from  ethanol. Yield : 54%; M.P. : 208°C, Rf : 0.49, (Required : C, 49.54% ;
H, 4.16%;N, 21.01% for C11H9N4O2Cl, Found : C, 49.48%; H, 4.10%;N,
20.95% )
.
(B) Prepara t ion  o f  2-Hydroxy-4 - (p -acetamidophenyl  su lphonyl
          amino)-5-carboxamido-6-(p-chlorophenyl) pyrimidine  (XIIIe).
A mixture of 2-Hydroxy-4-amino-5-carboxamido-6-(p-chlorophenyl)
pyrimidine (2.66gm, 0.01M)  and  p-acetamidophenyl sulphonylchloride
(2.33 gm, 0.01M) in pyridine (15 ml) was heated under reflux condition for five
hrs. The content was poured into crushed ice. Filtered the product and
recrystallized from ethanol. Yield : 60%, M.P. : 217°C, Rf1
 : 0.61,Rf2
 :  0.54
(Required :C, 47.75%; H, 3.35%; N, 1 5.17% for C 19H16N5O6SCl, Found :
C, 47.70% ; H, 3.30%; N, 15.12)
Similarly, other compounds (XIIIa-j) were synthesized. The physical data are
recorded in Table No. 13
(C) Ant imicrobia l  act iv i ty  o f  2 -Hydroxy-4- (p-acetamidophenyl
su lphonylamino)-5-carboxamido-6-aryl pyrimidines (XIIIa-j).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 43. The MIC values of test solution are recorded in Table No.
13a,13b,13c.
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SECTION - II
PREPARATION AND BIOLOGICAL EVALUATION OF 2-HYDROXY-4-(p-
AMINOPHENYL SULPHONYLAMINO)-5-CARBOXAMIDO-6-ARYL PYRIM-
IDINES
Looking to the biodynamic activities226-259 and the other properties206-225
of sulphonamides and in order to have highly potent therapeutic agents, the
synthesis of 2-hydroxy-4-(p-aminophenyl sulphonylamino)-5-carboxamido-
6-aryl pyrimidines (XIVa-j) have been undertaken by the hydrolysis of 2-hydroxy-
4-(p-acetamidophenyl sulphonylamino)-5-carboxamido-6-aryl pyrimidines
with hydrochloric acid.
The constitution of the products (XIVa-j) have been delineated by elemen-
tal analyses, IR, PMR  and Mass spectral data.
The products (XIVa-j) were assayed for their in vitro  biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227  at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum In-
hibitory  Concentration) values. The biological activities of the synthesized com-









   ( XIVa-j )                                    R=Aryl
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        Type             Vibration Mode             Frequency in cm-1             Reference.
                   Observed       Reported
  IR SPECTRAL STUDY OF 2-HYDROXY-4-(p-AMINO PHENYL SULPHONYL
 AMINO)-5-CARBOXAMIDO-6-(p-METHOXYPHENYL) PYRIMIDINE  (XIVh)
 Alkane
 CH3
  Aromatic and
  Pyrimidine
   moiety









C=C + C=N and ring
 skeletal vibration
 C-H str.
 C-H i.p. def.
 C-H o.o.p. def.
 C-O-C str. (asym.)






 S=O str. (asym)
 S=O str. (sym)
 C=N  str.
 N -N  def.
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PMR SPECTRAL STUDY OF 2-HYDROXY-4-(p-AMINO PHENYL SULPHONYL
-AMINO)-5-CARBOXAMIDO-6-(p-METHOXY PHENYL) PYRIMIDINE  (XIVh)
       1
       2
       3
       4
       5
       6
       7
  Signal
    No
    Signal position
      (d  ppm)
    Relative No.
     of Protons    Multiplicity       Inference
      3.885
      7.042-7.049
      7.306-7.337
      7.523-7.552
      8.157-8.186
      8.238
      8.765
       3H
       2H
       2H
       2H
       2H
       2H
       1H
    singlet
   doublet
   doublet
   doublet
   doublet
    singlet
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     (XIVa-j) R=Aryl
Studies  on  pyrimidinyl  sulphonamides 209
EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 2-HYDROXY-4-(p-
A M I N O P H E N Y L S U L P H O N Y L A M I N O ) - 5 - C A R B O X A M I D O - 6 - A R Y L
PYRIMIDINES  (XIVa-j)
(A) Preparat ion  of  2-Hydroxy-4- (p-acetamidophenyl  sulphonyl
          amino)-5-carboxamido-6-(p-methoxyphenyl) pyrimidine  (XIIIh).
For preparation refer part-III, section I ,pageno.198.
(B) Preparation of 2-Hydroxy-4-(p-amino phenyl sulphonylamino)-5-
carboxamido-6-(p-methoxyphenyl) pyrimidine  (XIVh).
A mixture of 2-hydroxy-4-(p-acetamidophenyl sulphonylamino)-5-
carboxamido-6-(p-methoxyphenyl) pyrimidine  (4.57gm, 0.01M) was dissolved
in concentrated hydrochloric acid (20ml) and heated under reflux condition for
five hrs. The content was poured into ice cold water and filtered. The product was
isolated and crystallized from ethanol. Yield : 59%, M.P. : 159°C, Rf1
 : 0.58,
Rf2
 : 0.53 ( Required :   C, 52.04%; H, 4.09%; N, 16.87% for C 18H17N5O5S,
Found : C, 51.99%;  H, 4.03%; N, 16.82%)
.
Similarly, other compounds (XIVa-j) were synthesized. The physical data
are recorded in Table No. 14
(C) Antimicrobial activity of 2-Hydroxy-4-(p-amino phenyl sulphonyl
          amino)-5-carboxamido-6-aryl pyrimidines (XIV a-j).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 43. The MIC values of test solution are recorded in Table No.
14a,14b,14c.
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P A R T - I V
S T U D I E S  O N
 P Y R I M I D O [ 4 , 5 - d ] P Y R I M I D I N E S




Pyrimido[4,5-d]pyrimidines(68) is a fused heterocyclic compound in which
one of the pyrimidine with its 4,5-position is fused with another pyrimidine hetero
cyclic ring system with itsd-position.
                                                 (68)
Pyrimido[4,5-d]pyrimidine
In 1938 F.Bergel et al.,260 have synthesized 1,4 (or 3,4)-dihydro-2,7-dimethyl
pyrimido[4,6-d] pyrimidine. Pyrimido[4,5-d]pyrimidine ring system isomeric with
the pteridine (69)ring and therefore, is of interest as a modal for biologically ac-
tive compound.
   Pteridine
There are other four possible isomers of pyrimido[4,5-d]pyrimidines which
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SYNTHETIC METHODS OF PYRIMIDO[4,5-d] PYRIMIDINE
Several attempts have been made for the synthesis of pyrimido[4,5-d]
pyrimidines , some of them are describes as under.
(1) By the cyclocondensation of 4-thiomethyl-5-substituted uracil with
formamide  led to the formation of pyrimido [4,5-d]pyrimidines261
(2) By the cyclocondensation of b -arylidene malononitrile  with thiourea
followed by reaction in nitrogen and oxygen atmosphere led to the
formation ofpyrimido[4,5-d] pyrimidines262
(3) By the cyclocondensation of 4-(p-substituted phenylamino)-5-carboxamido
pyrimidine with arylisocynate led to the formation of pyrimido[4,5-d]
pyrimidines263
(4) By the cyclocondensation of 4-amino pyrimidine with formamide  at 1500C
led to the formation of 2,4-disubstituted pyrimido[4,5-d] pyrimidines264
(5) By the heating of 6-amino-5-(N-carboxy carboxamido)uracil led to the
formation of pyrimido [4,5-d] pyrimidines265
(6) By the cyclocondensation of 4-amino-5-carboxamido-6-substituted pyrimidine
with ethylacetate led to the formation of pyrimido[4,5-d] pyrimidines266
(7) By the cyclocondensation of 5-carbamoyl-2,4-pyrimidine diamine with 1,1,1-
triethoxy methane  and 1,1,1-triformamido methane  led to the formation
of pyrimido[4,5-d] pyrimidines267
(8) By the cyclocondensation of 4-amino-5-cyano-6-aryl-2-thioxo(3H) pyrimidine
with carbondisulphide  led to the formation of 4-aryl-2,5,7-trithioxo-1,6,8-
trihydro pyrimido[4,5-d] pyrimidines268
THERAPEUTIC IMPORTANCE OF PYRIMIDO[4,5-d] PYRIMIDINE
The pyrimido[4,5-d]pyrimidines are reported to exhibit a wide variety
of therapeutic activities such as;
 (a) Diuretic269-272  (b) Antihypertensive273
 (c) CNS-depressant274-275  (d) Antimalarial276
 (e) Platelate aggregation277  (f) Antibacterial278-284
 (g) Anticonvulsant285  (h) Antithrombicagent286
 (i) Coronary vasodilator287-288   (j) Antitumor289
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A.Takamisawa et al.,290 have synthesized pyrimido benzothiazine(74)
as sedative and analgesic.Chaitanya dave et al.,291 have synthesised 3-substi-
tuted 2-thioxo-5,7-dimethyl pyrido[2,3-d]pyrimidine-4-(3H)-ones  and their S-
alkylation (75) as dihydrofolate and antitumor agents.





















Aleen G. et al.,292 have synthesized  non classical 2-Amino-4-oxo-6-
(arylthio)ethyl pyrrolo[2,3-d] pyrimidines(76) as Antifolates.T.J.Delia et al.,293
have synthesised 6-benzyl or phenetyl -2,4-diamino-5,6,7,8-tetrahydro



















S.Yurugi et al.,294 have synthesized 5,7-disubstituted amino-2-phenyl
pyrimido[4,5-d] pyrimidines  (78) as diuretic.Recently, A. Nagarajan et al.,295 have
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Anita Devi et al.,296 have synthesized 2- amino-6,8-diphenyl-oxo-pyrimido[4,5-
d ] pyrimidine-7-thiones (80,81)  and screened for antifungal activity at different
concentration and result were compared with commercial fungicide carbendazim
















In view of procuring highly potent biodynamic agents and after reviewing
literature survey on pyrimido[4,5-d] pyrimidines for their various methods of syn-
thesis and different biological activities, synthesis of pyrimido[4,5-d] pyrimidines
have been undertaken which can be summarized in the following sections as under.
SECTION - I :  P R E P A R A T I O N  A N D  B I O L O G I C A L  E V A L U A T I O N  OF
                         2-ARYL-5-PHENYL-7-MERCAPTO-4-ONE-1,2,3-TRIHYDRO-
                          PYRIMIDO[4,5-d] PYRIMIDINES.
SECTION - II : P R E P A R A T I O N  A N D  B I O L O G I C A L  E V A L U A T I O N  OF
                         2-ARYL-2-METHYL-5-PHENYL-7-MERCAPTO-4-ONE-1,2,3-
                         TRIHYDRO PYRIMIDO[4,5-d] PYRIMIDINES.
221Studies  on PYRIMIDO[4 ,5 -D]pyrimidines
SECTION - I
PREPARATION AND BIOLOGICAL EVALUATION OF 2-ARYL-5-PHENYL-7-
MERCAPTO-4-ONE-1,2,3-TRIHYDRO PYRIMIDO[4,5-d] PYRIMIDINES
Due to other propert ies 260-268 and biodynamic act iv i t ies 269-296
of pyrimido[4,5-d]pyrimidines and with a view to have potent therapeutic agents,
the synthesis of 2-aryl-5-phenyl-7-mercapto-4-one-1,2,3-trihydro pyrimido[4,5-
d] pyrimidines(XVa-j) have been undertaken by the condensation of different
2-mercapto-4-amino-5-carboxamido-6-phenyl pyrimidines  with aromatic al-
dehydes.
The constitution of the products (XVa-j) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (XVa-j) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) :  0 (control), 5, 10, 25, 50, 100, 200, 500  for their MIC (Minimum In-
hibitory  Concentration) values. The biological activities of the synthesized com-








( XVa-j )                                              R=Aryl
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 IR SPECTRAL STUDY OF 2-(p-METHOXY PHENYL)-5-PHENYL-7-MERCAPTO-4-
 ONE-1,2,3-TRIHYDRO PYRIMIDO[4,5-d] PYRIMIDINE (XVh)
     Type
 Alkane
 CH3











 C=C + C=N and ring
skeletal  vibration
 C-H str.
 C-H i.p. def.
 C-H o.o.p. def.
 C-O-C str. (asym.)
 C-O-C str. (sym.)
  N-H str(1st)




   2923.9
   2862.2
   1452.3
   1367.4
   1508.2
   1560.3
   3060.8
   1112.8
     813.9
   1226.6
   1056.9
   3419.6
   3381.0
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PMR SPECTRAL STUDY OF 2-(p-METHOXY PHENYL)-5-PHENYL-7-
MERCAPTO-4-ONE-1,2,3-TRIHYDRO PYRIMIDO[4,5-d]PYRIMIDINE  (XVh)
       1
       2
       3
       4
       5
  Signal
    No
    Signal position
      (d  ppm)
    Relative No.
     of Protons    Multiplicity       Inference
      3.882
      7.030-7.039
      7.410-7.500
      7.766-7.810
      9.008
       3H
       2H
       5H
       3H
       1H
    singlet
   doublet
   multiplet
   multiplet










































































































































































































































  REACTION SCHEME
(XVa-j) R=Aryl
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 2-ARYL-5-PHENYL-7-
MERCAPTO-4-ONE-1,2,3-TRIHYDRO PYRIMIDO[4,5-d] PYRIMIDINES
(A) Preparat ion  of  2-Mercapto-4-amino-5-carboxamido-6-phenyl
pyrimidine.
2-Mercapto-4-amino-5-cyano-6-phenyl pyrimidine(2.30 gm, 0.01M) was
dissolved in concentrated sulphuric acid (20ml) below 5 oC and kept for 48 hrs.
at room temperature. The content was poured into ice cold water  and filtered.
The product was isolated and crystallized from ethanol. Yield : 58%, M.P. :
168°C,   R f1
 : 0.51, R f2
 : 0.60 (Required :C, 53.64%; H, 4.09%; N, 22.75% for
C11H10N4OS, Found : C, 53.59%; H, 4.04%; N, 22.69%)
(B) Preparation of 2- (p-methoxy phenyl)-5-phenyl-7-mercapto-4-one-
          1,2,3-trihydro pyrimido [4,5-d] pyrimidine  (XVh).
A mixture of 2-Mercapto-4-amino-5-carboxamido-6-phenyl pyrimidine
(2.46gm, 0.01M) and p-anisaldehyde (1.36ml, 0.01M) in gla.CH3COOH  (30 ml)
was heated under reflux condition for six hrs. The content was poured into ice
cold water and filtered. The product was isolated and crystallized from
ethanol:dioxan(2:1). Yield : 64%, M.P. : 108°C, Rf1
 : 0.55, R f2
 : 0.59  (Required :
C, 62.64%; H, 4.12%; N, 15.38% for C19H16N4O2S, Found : 62.58%; H,
4.07%;   N, 15.32%)
.
Similarly, other compounds (XVa-j) were synthesized. The physical data
are recorded in Table No. 15.
(C) Antimicrobial activity of 2-aryl-5-phenyl-7-mercapto-4-one-1,2,3-
          trihydro pyrimido [4,5-d] pyrimidines   (XVa-j).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 43. The MIC values of test solution are recorded in Table No.
15a,15b,15c.
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SECTION - II
PREPARATION AND BIOLOGICAL EVALUATION OF 2-ARYL-2-METHYL-5-
PHENYL-7-MERCAPTO-4-ONE-1,2,3-TRIHYDRO PYRIMIDO[4,5-d]PYRIMIDINES
Due to other propert ies 260-268 and biodynamic act iv i t ies 269-296
of pyrimido[4,5-d]pyrimidines and with a view to have potent therapeutic agents,
the synthesis of 2-aryl-2-methyl-5-phenyl-7-mercapto-4-one-1,2,3-trihydro
pyrimido[4,5-d] pyrimidines(XVI a-h) have been undertaken by the condensa-










The constitution of the products (XVIa-h) have been delineated by elemen-
tal  analyses, IR, PMR  and Mass spectral data.
The products (XVIa-h) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) :  0 (control), 5, 10, 25, 50, 100, 200, 500  for their MIC (Minimum In-
hibitory  Concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
( XVIa-h )                                                 R=Aryl
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  IR SPECTRAL STUDY OF 2-(p-CHLORO PHENYL)-2-METHYL-5-PHENYL-
  7-MERCAPTO-4-ONE-1,2,3-TRIHYDRO PYRIMIDO[4,5-d]PYRIMIDINE (XVId )
     Type
 Alkane
 CH3











 C=C + C=N and ring
skeletal  vibration
 C-H str.
 C-H i.p. def.
 C-H o.o.p. def.
  N-H str(1st)
  N-H def(2nd)
 C=O str
 C -Cl str.
Frequency in cm-1
Observed
   2933.9
   2873.7
   1458.1
   1367.4
   1508.2
   1546.8
   3066.8
   1112.8
     825.5
   3452.3
   3328.9
   1668.3
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PMR SPECTRAL STUDY OF 2-(p-CHLOROPHENYL)-2-METHYL-5-PHE-
NYL-7-MERCAPTO-4-ONE-1,2,3-TRIHYDRO PYRIMIDO[4,5-d]PYRIMIDINE
(XVId)
       1
       2
       3
       4
       5
       6
  Signal
    No
    Signal position
      (d  ppm)
    Relative No.
     of Protons    Multiplicity       Inference
      2.431
      7.309-7.335
      7.374-7.522
      7.804-7.833
      8.381
      9.024
       3H
       2H
       5H
       3H
       1H
       1H
    singlet
   doublet
   multiplet
  doublet
   singlet
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(XVIa-h)              R=Aryl
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 2-ARYL-2-METHYL-5-
PHENYL-7 -MERCAPTO-4 -ONE-1 ,2 ,3 -TR IHYDROPYRIMIDO[4 ,5 -d ]
PYRIMIDINES
(A) Preparat ion  of  2-Mercapto-4-amino-5-carboxamido-6-phenyl
          pyrimidine (XVh)
Refer part-IV section-I page no.227.
(B) Preparation of 2- (p-chloro phenyl)-2-methyl-5-phenyl-7-mercapto-
4-one-1,2,3-trihydro pyrimido [4,5-d] pyrimidine  (XVId)
A mixture of 2-Mercapto-4-amino-5-carboxamido-6-phenyl pyrimidine
(2.46gm, 0.01M) and p-chloro acetophenone  (1.54ml, 0.01M) in gla.CH3COOH
(30 ml) was heated under reflux condition for six hrs. The content was poured into
ice cold water and filtered. The product was isolated and crystallized from
ethanol:dioxan(2:1) . Yield : 53%, M.P. : 150°C, Rf 1
 :  0 .54,  Rf2
 :  0.49
(Required :C, 59.61%; H, 3.92%; N, 14.64% for C 19H15N4OSCl, Found : C,
59.55%; H, 3.87%;N, 14.58% )
.
Similarly, other compounds (XVIa-j) were synthesized. The physical data
are recorded in Table No. 16.
(C) Antimicrobial activity of 2-aryl-2-methyl-5-phenyl-7-mercapto-
4-one-1,2,3-trihydro pyrimido [4,5-d] pyrimidines  (XVIa-h).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 43. The MIC values of test solution are recorded in Table No.
16a,16b,16c.
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PART - V
STUDIES ON 1,4-DIHYDRO PYRIDINE DERIVATIVES
INTRODUCTION
In 1,4- dihydropyridine  either imino (NH) or substituted nitrogen atom is
present at one position and hydrogen atom at four position of the six membered
hetrocyclic ring which can be represented as under. (82).
        R1 , R4  = H / Alkyl / Aryl
         R2 , R6  = Methyl
                                                            R3,R5  = Acetyl /Carbmethoxy/
                         Carbethoxy / N-Aryl Carbamoyl
1,4-dihydropyridine contribute as an important class of compound in
medicinal  chemistry,  leading to several new drugs currently  widely used especially as
calcium channel antagonist297 and other cardiovascular diseases also.
SYNTHETIC METHODS OF 1,4-DIHYDRO PYRIDINES
B.Chekavichus et al.304 has proposed following kind of successive












































(B)(C)R,R1= Alkyl / Aryl
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The synthesis of 1,4-dihydro pyridines  involves following steps.
(1) Intermediate (A) involves cyclisation of 3-aryl-aminocrotonate and arylidene
followed by the rearrangement of hydrogen.
(2) Intermediate (B) involves dehydration of  (A) with loss of equimolar quantity
of water.
(3) Intermediate (C) involves isomerisation of intermediate of (B) and obtained
regio and stereo selective 1,4-dihydro pyridine  as a final product .
It has been observed that in the presence of piperidine as a catalyst ,
pyran was formed as an intermediate by the cyclocondensation of aliphatic or
aromatic aldehydes  with 1,3-diketones , followed by the dehydration of pyran
through the reaction with aliphatic or aromatic amines affored final product.




































R, R3 = H / Aryl / Aryl
R1, R4 = Carboxylate/ Arylcarbamoyl






































































(1) Abstraction of proton by base  from ethyl aceto acetate  form nucleophile.
(2) Attack of nucleophile on aldehyde  molecule to yield bis-keto ester .
(3) Condensation of NH3 with bis-keto ester with removel of water molecule to
give 1,4-dihydro pyridine  derivative.
SYNTHETIC METHODS OF  1,4-DIHYDRO PYRIDINES
Different synthetic methods for the synthesis of 1,4-dihydropyridine  are
as follows.
(1) By the condensation of aromatic or aliphatic aldehydes with acetoacetate
ester and aromatic or aliphatic amine  in presence of pyridine 298-301.
(2) By the condensation of aliphatic or aromatic aldehydes with 3-amino
crotonate  and 1,3 -diketone  302-309.
(3) By the condensation of arylidine  with 3-aminocrotonate310.
(4) By the condensation of aliphatic or aromatic aldehydes  with various 1,3-
diketones  in presence of ammonia  or ammonium carbonate311-313.
(5)        By the condensation of a.b  -unsaturated ketones  with malononitrile  and
cyanoacetamide 314 .
(6)       By the condensation of o-nitrobenzaldehyde, b  -amino butaricacid  and
methylpripiolate in glacial acetic acid315 .
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(7) By the knoevenagel condensation of benzaldehyde  with acetoaceticester
in presence of b -alanine as catalyst and subsequent cyclocondensation
of theresulting benzylidene  with 3-amino crotonate316 .
(8)       By the regio and chemoselective addition of  Ph2Cu(CN)Li2 to substituted
N-alkyl pyridium salts followed by acylation of the intermediate 317 .
(9)       By the condensation of 1,3-diketones ,alkyl or aryl aldehydes with aqueous
ammonium hydroxide  in the presence of piperidine or piperidyl acetate
or potassium acetate or potassium carbonate or glacial acetic acid318-320 .
(10)    By the condensation of two moles of thiobarbituric acid , aromatic amines
and aromatic aldehydes321-322.
THERAPEUTIC IMPORTANCE OF 1,4-DIHYDRO PYRIDINES
The research on 1,4-dihydropyridine  system is of current interest due to
their valuable activities as calcium channel antagonist , vasodilator , cardio-
vascular etc. beside the currently established drugs Nifedipine323-324
,Nicardipine325-326  Many dihydropyridine derivatives have been synthesized
world wide327-337. and have led to numerous second generation commercial
product331-338. such as Nimodipine 339-340, Nisodipine341, Nitrendipine 342,
Amlodopine 343 ,  Felodip ine 344 , Isradipine 345 , Manidip ine 346  and
Nelvadipine 347. Some of their compounds are characterized by longer bioactiv-
ity of greater tissue selectivity. 1,4-dihydropyridine  derivatives are associated
with diverse biological activities viz.
(a) Antiarythemic348 (b) Antiinflammatory349
(c) Antiallergic350 (d) Antiulcer351
(e) Antitumor301 (f) Vasodilator352
(g) Enzymetic353-354 (h)   Calcium channel antagonist 355-357
(i) Antihypertensive358-359 (j) Antihypolipemic360
(k) Antimayocardic ischemic361 (l) Cardiovascular362
(m) Photo induced relaxation305,315 (n) Antitubercular agents363
I. Nadeem et al.308 (83) have demonstrated the structure function rela-
tionship of calcium channel and photo induced relaxation of novel 1,4- dihydro
pyridines.  Activities of calcium channel antagonists invitro were detected
and gave such conclusion about structure-activity relationship(SARs) .
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(1) Relative potency order for C-4 phenyl substituents is ortho ans meta is
greater  then pera.





       (83)                R 1=COOCH3 / COOC2H5
      R2=COOCH3 / COOC2H5
    R3 =Substituted phenyl
G. Charles et al.364 (84) have synthesized 1,4-dihydropyridines
















       (84)   (85)
Dihydro pyridine derivatives (84) have been found to be useful in treat-
ing benign prostate hyperplasia inhibition of cholesterol synthesis (85) showed
‘ki’ of  1.9 m.mol/kg.In reducing urethral pressure invivo in dog. More recently
B.M. Khadikar et al.365 prepared 1,4-dihydro pyridine derivatives (86) and
tested its biological activity.
Out of many 1,4-dihydro pyridine  drugs only Flordipine (87) is N-substi-
tuted derivative that has proved to be very good calcium channel antagonist ,
contrary to be belief proposed by D.J.Triggle 366 that N-substituted 1,4-dihydro
pyridine was not shown good antihypertensive activity , probably the concept of that time
and -NH was belived to essential for calcium channel antagonism.



















                     (86)                                                                                         (87)
          R1=Methyl/ethyl, R2=Methyl/ethyl
          R=Alkyl/Aryl
N-methyl nimodipine (88) was found to possess antidepressive 367 char-
acteristics (20 mg.P.O reduce the immobile phase by approximately 22% com-
parison to control values), which provides excellent example of mechanism of















                                     (88)                                                                 (89)
V. Michael et.al.368 prepared antihypertensive and coronary vasodila-
tor N-substituted 1,4-dihydro pyridine(89).
Adam Daich et. al.369 prepared calcium antagonist effect of 1,4-dihydro
pyridine (90) and Margarita Suarez et.al.370 prepared Calcium antagonist
modulators 1,4-dihydro pyridine  (91).


















                    (90)   X=O, S, NR5                                                 (91)
In view of procuring highly potent biodynamic agents and after reviewing
literature survey on 1,4 dihydro pyridines  for their various methods of synthesis
and different biological activities, synthesis of 1 ,4 dihydro pyridines  have been
under taken which can be summarized in the following sections as under.
SECTION - I :  P R E P A R A T I O N  A N D  B I O L O G I C A L  E V A L U A T I O N  OF
                         1-N-ARYL-2,6-DIMETHYL-4-(1’-N-PHENYL-3’-(p-METHYL
               PHENYL)  PYRAZOL-4’ -YL)-3 ,5-DICARBETHOXY-1,4-
     DIHYDRO PYRIDINES.
SECTION - II : P R E P A R A T I O N  A N D  B I O L O G I C A L  E V A L U A T I O N  OF
                         1-N-ARYL-2,6-DIMETHYL-4-(1’-N-PHENYL-3’-(p-METHYL
               PHENYL) PYRAZOL-4’-YL)-3,5-DICARBMETHOXY-1,4-
     DIHYDRO PYRIDINES.
SECTION - III : PREPARATION AND BIOLOGICAL EVALUATION OF
                         1-N-ARYL-2,6-DIMETHYL-4-(1’-N-PHENYL-3’-(p-BROMO
               PHENYL) PYRAZOL-4’-YL)-3,5-DICARBETHOXY-1,4-
     DIHYDRO PYRIDINES.
SECTION - IV: P R E P A R A T I O N  A N D  B I O L O G I C A L  E V A L U A T I O N  OF
                         1-N-ARYL-2,6-DIMETHYL-4-(1’-N-PHENYL-3’-(p-BROMO
               PHENYL) PYRAZOL-4’-YL)-3,5-DICARBMETHOXY-1,4-
     DIHYDRO PYRIDINES.
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SECTION - I
PREPARATION AND BIOLOGICAL EVALUATION OF 1-N-ARYL-2,6-DIM-
ETHYL-4-(1’-N-PHENYL-3’-(p-METHYLPHENYL)-PYRAZOL-4’-YL)-3,5-
DICARBETHOXY-1,4-DIHYDRO PYRIDINES.
Due to other propert ies 297-347 and biodynamic act iv i t ies 348-373
of1,4-dihydro pyridines  and with a view to have potent therapeutic agents, the
synthesis of 1-N-aryl-2,6-dimethyl-4-(1’-N-phenyl-3’-(p-methyl phenyl)-pyrazol-
4’-yl)-3,5-dicarbethoxy-1,4-dihydro pyridines (XVII a-l) have been undertaken
by the condensation of 1-N-phenyl-3-(p-methyl phenyl)-4-formyl pyrazole








The constitution of the products (XVIIa-l) have been delineated by elemen-
tal  analyses, IR, PMR  and Mass spectral data.
The products (XVIIa-l) were assayed for their in vitro biological assay
like  antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-
96 (Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441  (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227  at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum In-
hibitory  Concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
(XVII a-l )                                  R=Aryl
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 IR SPECTRAL STUDY OF 1-N-(p-METHOXY PHENYL)-2,6-DIMETHYL-4-(1’-
 N- PHENYL-3’-(p- METHYL PHENYL)-PYRAZOL-4’-YL)-3,5-DICARBETHOXY -
 1,4-DIHYDRO PYRIDINE (XVIIg)
     Type
 Alkane
 CH3
   Aromatic










 C-H i.p. def.
 C-H o.o.p. def.
 C-O-C str. (asym.)
 C-O-C str. (sym.)
 C=N  str
 N -N  def
 C -N str
 C=O str.
 C-O-C str. (asym.)
 C-O-C str. (sym.)
Frequency in cm-1
   2931.6
   2866.0
   1463.9
   1350.1
   3010.7
   1546.8
   1199.1
   1261.4
   1483.2
   1627.8
   1575.7
   1066.6
   1678.0
   1234.3
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PMR SPECTRAL STUDY OF 1-N-(p-METHOXY PHENYL)-2,6-DIMETHYL-
4-(1’-N-PHENYL-3’-(p-METHYL PHENYL)-PYRAZOL-4’-YL)-3,5-DICARB-
ETHOXY-1,4-DIHYDRO PYRIDINE  (XVIIg)
       1
       2
       3
       4
       5
       6
       7
       8
       9
      10
      11
  Signal
    No
    Signal position
      (d  ppm)
    Relative No.
     of Protons    Multiplicity       Inference
      1.102
      1.999
      2.413
      3.787
      3.763
      3.976
      5.409
      6.962-7.004
      7.246-7.461
      7.685-7.715
      7.810-7.840
       6H
       6H
       3H
       3H
       2H
       2H
       1H
       4H
       5H
       2H
       3H
    triplete
   singlet
   singlet
   singlet
   quartet
   quartet








































































































































































































































































































































                                                           REACTION SCHEME
(XVIIa-l)                         R = Aryl
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  EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 1-N-ARYL-2,6-DIM-
ETHYL-4-(1’-N-PHENYL-3’-(p-METHYLPHENYL)-PYRAZOL-4’-YL)-3,5-
DICARBETHOXY-1,4-DIHYDRO PYRIDINES.
(A) Preparation of1-N-(p-methoxy phenyl) -  2 ,6-dimethyl-4- (1’-N-phenyl-
3’-(p-methylphenyl)-pyrazol-4’-yl)-3,5-dicarbethoxy 1,4-dihydro
pyridines (XVIIg)
A mixture of 1-N-phenyl-3-(p-methyl phenyl)-pyrazol-4-carboxaldehyde
(2.62gm, 0.01M), ethyl aceto acetate  (2.60ml, 0.02M) and p-anisidine  (1.23gm,
0.01M) in ethanol (30 ml) was heated under reflux condition for six hrs. The con-
tent was poured into  ice cold water.  The seperated solid was filtered and crystal-
lized from DMF:dioxan (2:1).  Yield : 64%, M.P. : 173°C, Rf1
 : 0.63,  Rf2
 : 0.56
(Required : C, 73.10%; H, 6.26%; N, 7.11% for C 36H37N3O5, Found :
C, 73.05%; H, 6.20%; N, 7.07%)
Similarly, other compounds (XVIIa-l) were synthesized. The physical data
are recorded in Table No.17.
(C) Antimicrobial activity of 1-N-aryl -  2 ,6-dimethyl-4- (1’-N-phenyl-3’-(p-
methylphenyl)-pyrazol-4’-yl)-3,5-dicarbethoxy 1,4-dihydro pyridines
(XVIIa-l).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No.43. The MIC values of test solution are recorded in Table No.
17a,17b,17c.
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Studies  on  1 ,4  d ihydro pyridines 264
SECTION - II
PREPARATION AND BIOLOGICAL EVALUATION OF 1-N-ARYL-2,6-DIMETHYL-4-(1’-
N-PHENYL-3’-(p-METHYLPHENYL)-PYRAZOL-4’-YL)-3,5-DICARBMETHOXY-1,4-
DIHYDRO PYRIDINES.
Due to other propert ies 297-347 and biodynamic act iv i t ies 348-373
of 1,4-dihydro pyridines  and with a view to have potent therapeutic agents, the
synthesis of 1-N-aryl-2,6-dimethyl-4-(1’-N-phenyl-3’-(p-methyl phenyl)-pyrazol-
4’-yl)-3,5-dicarbmethoxy-1,4-dihydro pyridines  (XVIII a-l) have been under-
taken by the condensation of 1-N-phenyl-3-(p-methyl phenyl)-4-formyl








The constitution of the products (XVIIIa-l) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (XVIIIa-l) were assayed for their in vitro biological assay
like  antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-
96 (Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441  (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227  at different concentrations
(µg/ml) :  0 (control), 5, 10, 25, 50, 100, 200, 500  for their MIC (Minimum In-
hibitory  Concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
(XVIIIa-l )                                  R=Aryl
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  IR SPECTRAL STUDY OF 1-N-(p-METHOXY PHENYL)-2,6-DIMETHYL-4-(1’-N-
  PHENYL-3’-(p-METHYL PHENYL) PYRAZOL-4’-YL)-3,5-DICARBMETHOXY-
 1,4- DIHYDRO PYRIDINE(XVIIIg)














 C-H i.p. def.
 C-H o.o.p. def.
 C-O-C str. (asym.)
 C-O-C str. (sym.)
 C=N  str
 N -N  def
 C -N str
 C=O str.
 C-O-C str. (asym.)
 C-O-C str. (sym.)
Frequency in cm-1
Observed
   2929.9
   2850.6
   1442.7
   1334.6
   3041.5
   1514.0
   1132.1
   1269.1
   1498.6
   1616.2
   1585.4
   1184.2
   1672.2
   1232.4
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PMR SPECTRAL STUDY OF 1-N-(p-METHOXY PHENYL)-2,6-DIMETHYL-
4-(1’-N-PHENYL-3’-(p-METHYL PHENYL) PYRAZOL-4’-YL)-3,5-DICARB-
METHOXY-1,4-DIHYDRO PYRIDINE (XVIIIg)
       1
       2
       3
       4
       5
       6
       7
       8
       9
  Signal
    No
    Signal position
      (d  ppm)
    Relative No.
     of Protons    Multiplicity       Inference
      2.042
      2.414
      3.374
      3.870
      5.381
      7.011-7.040
      7.254-7.463
      7.688-7.714
      7.808-7.843
       6H
       3H
       6H
       3H
       1H
       4H
       5H
       2H
       3H
   singlet
   singlet
   singlet
   singlet
   singlet
   multiplet
















































































































































































































































































































































                                                           REACTION SCHEME
    (XVIIIa-l) R=Aryl
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 1-N-ARYL-2,6-DIM-
ETHYL-4-(1’-N-PHENYL-3’-(p-METHYLPHENYL)-PYRAZOL-4’-YL)-3,5-
DICARBMETHOXY-1,4-DIHYDRO PYRIDINES.(XVIIIa-l)
(A) Preparation of1-N-(p-methoxy phenyl) -  2 ,6-dimethyl-4- (1’-N-phenyl-
3’-(p-methyl phenyl)-pyrazol-4’-yl)-3,5-dicarbmethoxy 1,4-dihydro
pyridines (XVIIIg).
A mixture of 1-N-phenyl-3-(p-methyl phenyl) pyrazol-4-carboxaldehyde
(2.62gm, 0.01M), methyl aceto acetate (2.32ml, 0.02M) and p-anisidine
(1.23gm, 0.01M) in ethanol (30 ml) was heated under reflux condition for six hrs.
The content was poured into ice cold water . The seperated solid was filtered
and crystallized from DMF:dioxan (2:1). Yield : 68%, M.P. : 216°C, R f1
 : 0.49,R f2
: 0.56 (Required :C, 72.47%; H, 5.86%; N, 7.46% for C 34H33N3O5, Found :
C, 72.42%; H, 5.80%; N, 7.41%)
.
Similarly, other compounds (XVIIIa-l) were synthesized. The physical data
are recorded in Table No. 18.
(C) Antimicrobial activity of 1-N-aryl -  2 ,6-dimethyl-4- (1’-N-phenyl-3’-(p-
methylphenyl)-pyrazol-4’-yl)-3,5-dicarbmethoxy 1,4-dihydro pyridines
(XVIIIa-l).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 43. The MIC values of test solution are recorded in Table No.
18a,18b,18c.
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SECTION - III
PREPARATION AND BIOLOGICAL EVALUATION OF 1-N-ARYL-2,6-DIMETHYL-4-(1’-
N-PHENYL-3’-(p-BROMO PHENYL)-PYRAZOL-4’-YL)-3,5-DICARBETHOXY-1,4-
DIHYDRO PYRIDINES.
Due to other properties297-347 and biodynamic activities348-373 of
1,4-dihydro pyridines  and with a view to have potent therapeutic agents, the
synthesis of 1-N-aryl-2,6-dimethyl-4-(1’-N-phenyl-3’-(p-bromo phenyl)-
pyrazol-4’-yl)-3,5-dicarbethoxy-1,4-dihydro pyridines  (XIX a-l) have been un-
dertaken by the condensation of 1-N-phenyl-3-(p-bromo phenyl)-4-formyl








The constitution of the products  (XIXa-l) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (XIXa-l) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227  at different concentrations
(µg/ml) :  0 (control), 5, 10, 25, 50, 100, 200, 500  for their MIC (Minimum In-
hibitory  Concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
( XIXa-l  )                                              R=Aryl
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  IR SPECTRAL STUDY OF 1-N-(p-METHYLPHENYL)-2,6-DIMETHYL-4-
  (1’-N-PHENYL-3’-(p-BROMO PHENYL)-PYRAZOL-4’-YL)-3,5-DICARB-
  ETHOXY-1,4-DIHYDRO PYRIDINE (XIXk)




   moiety
 Pyrazole
Carboxylate
    Vibration  mode
  C-H str.(asym.)
  C-H str.(sym.)
  C-H def.(asym.)
  C-H def.(sym.)
  C-H str.
  C-H i.p. def.
  C-H o.o.p. def.
  C=N  str.
  N -N  def.
  C -N str.
  C=O str.
  C-O-C str. (asym.)
  C-O-C str. (sym.)
Frequency in cm-1
   2918.1
   2866.0
   1442.6
   1326.9
   3060.8
   1552.6
   1110.9
   1618.2
   1581.5
   1139.8
   1687.6
   1261.5




























































    374
     ,,
     ,,
     ,,
    375
     ,,
     ,,
     ,,
     ,,
    376
      ,,
      ,,
    374
    376
      ,,
Studies  on  1 ,4  d ihydro pyridines 278
PMR SPECTRAL STUDY OF 1-N-(p-METHYL PHENYL)-2,6-DIMETHYL-
4-(1’-N-PHENYL-3’-(p-BROMO PHENYL)- PYRAZOL-4’-YL)-3,5-DICARBETHOXY-
1,4-DIHYDRO PYRIDINE (XIXk)
       1
       2
       3
       4
       5
       6
       7
       8
       9
      10
      11
  Signal
    No
    Signal position
      (d  ppm)
    Relative No.
     of Protons
   Multiplicity       Inference
      1.098
      2.007
      2.410
      3.781
      3.980
      5.397
      6.966-6.993
      7.245-7.470
      7.683-7.711
      7.842
     7.874-7.902
       6H
       6H
       3H
       2H
       2H
       1H
       2H
       7H
       2H
       1H
       2H
    triplete
   singlet
   singlet
   quartet
   quartet











































































































































































































































































































(M +2) (M +2) (M -1)
(XIXe )
(BP)





















                                                           REACTION SCHEME
   (XIXa-l) R=Aryl
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 EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 1-N-ARYL-2,6-DIM-
ETHYL-4-(1’-N-PHENYL-3’-(p-BROMOPHENYL)-PYRAZOL-4’-YL)-3,5-
DICARBETHOXY-1,4-DIHYDRO PYRIDINES.
(A) Preparation of 1-N-(p-methyl phenyl)-2 ,6-dimethyl-4- (1’-N-phenyl-
3’-(p-methyl phenyl)-pyrazol-4’-yl)-3,5-dicarbethoxy 1,4-dihydro
pyridines (XIXk)
A mixture of 1-N-phenyl-3-(p-bromol phenyl)-pyrazol-4-carboxaldehyde
(3.27gm, 0.01M), ethyl aceto acetate  (2.60ml, 0.02M) and p-toludine  (1.07gm,
0.01M) in ethanol (30 ml) was heated under reflux condition for six hrs. The con-
tent was poured into ice cold water.  The seperated solid was filtered and crystal-
lized from DMF:dioxan (2:1). Yield : 53%, M.P. : 221°C, Rf1
 : 0.53, Rf2
 : 0.61
(Required : C, 65.62%; H, 5.31%; N, 6.56% for C35H34N3O4Br, Found :
C, 65.56%; H, 5.25%; N, 6.51%)
.
Similarly, other compounds (XIXa-l) were synthesized. The physical data
are recorded in Table No. 19.
(C) Antimicrobial activity of 1-N-aryl -  2 ,6-dimethyl-4- (1’-N-phenyl-3’-(p-
bromophenyl)-pyrazol-4’-yl)-3,5-dicarbethoxy-1,4-dihydro pyridines
(XIXa-l)
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 43. The MIC values of test solution are recorded in Table No.
19a,19b,19c.




























































   




   
   
19
8 
   
   
   
 6
6 
   




   




   
   
   




























   
   
16
7
   





   




   
   
   




























   
   
23
6
   





   




   
   
   





























   
   
20
6
   





   




   
   
   


























   




   
   
22
5
   





   




   
   
   


























   




   
   
23
0
   





   




   
   
   


























   




   
   
21
0
   





   




   
   
   


























   




   
   
18
0
   





   




   
   
   


























   




   
   
24
4
   





   




   
   
   


























   




   
   
20
1
   





   




   
   
   


























   




   
   
22
1
   





   




   
   
   































   
   
18
8
   





   




   
   
   












































































   
   
   
   
   
   
   
   



















































   
R
f 1
   
   
   
R
f 2



































   
   
   
   
   
   
   
   
   
   


























   







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Studies  on  1 ,4  d ihydro pyridines 288
SECTION - IV
PREPARATION AND BIOLOGICAL EVALUATION OF 1-N-ARYL-2,6-DIMETHYL-4-(1’-
N-PHENYL-3’-(p-BROMO PHENYL)-PYRAZOL-4’-YL)-3,5-DICARBMETHOXY-1,4-
DIHYDRO PYRIDINES.
Due to other propert ies 297-347 and biodynamic act iv i t ies 348-373
of1,4-dihydro pyridines  and with a view to have potent therapeutic agents, the
synthesis of 1-N-aryl-2,6-dimethyl-4-(1’-N-phenyl-3’-(p-bromo phenyl)-
pyrazol-4’-yl)-3,5-dicarbmethoxy-1,4-dihydro pyridines  (XX a-l) have been
undertaken by the condensation of 1-N-phenyl-3-(p-bromo phenyl)-4-formyl








The constitution of the products (XXa-l) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (XXa-l) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227  at different concentrations
(µg/ml) :  0 (control), 5, 10, 25, 50, 100, 200, 500  for their MIC (Minimum In-
hibitory  Concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
( XXa-l )                                          R=Aryl
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  IR SPECTRAL STUDY OF 1-N-(p-METHYL PHENYL)-2,6-DIMETHYL-4-(1’-
 N-PHENYL-3’-(p-BROMO PHENYL)-PYRAZOL-4’-YL)-3,5-DICARBMETHOXY-
 1,4-DIHYDRO PYRIDINE(XXk)




   moiety
Pyrazole
Carboxylate





 C-H  str.
 C=C str.
 C-H  i.p. def.
 C=N  str.
 N -N  def.
 C -N str.
 C=O str.
 C-O-C str. (asym.)
 C-O-C str. (sym.)
Frequency in cm-1
Observed
   2929.7
   2854.5
   1446.5
   1357.8
   3068.5
   1541.0
   1498.6
   1616.2
   1585.4
   1184.2
   1689.5
   1247.8
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PMR SPECTRAL STUDY OF  1-N-(p-METHYLPHENYL)-2,6-DIMETHYL-
4-(1’-N-PHENYL-3’-(p-BROMO PHENYL) PYRAZOL-4’-YL)-3,5-DICARB-
METHOXY-1,4-DIHYDRO PYRIDINE (XXk)
       1
       2
       3
       4
       5
       6
       7
       8
       9
  Signal
    No
    Signal position
      (d  ppm)
    Relative No.
     of Protons    Multiplicity       Inference
      2.042
      2.417
      3.372
      5.364
      7.000-7.027
      7.245-7.475
      7.681-7.708
      7.823
      7.857-7.885
       6H
       3H
       6H
       1H
       2H
       7H
       2H
       1H
       2H
   singlet
   singlet
   singlet
   singlet
  doublet
   multiplet
   doublet
    singlet





  Ar-H(e,e’ )(J=8.1)
 Ar-H +Ar-H(g,g’)(J=8.4)


















































































































































































































































































































































                                                           REACTION SCHEME
(XXa-l) R=Aryl
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 1-N-ARYL-2,6-DIM-
ETHYL-4-(1’-N-PHENYL-3’-(p-BROMOPHENYL)-PYRAZOL-4’-YL)-3,5-
DICARBMETHOXY-1,4-DIHYDRO PYRIDINES
(A) Preparation of1-N-(p-methyl phenyl)-2,6-dimethyl-4-(1’-N-phenyl-
3’-(p-bromo phenyl)-pyrazol-4’-yl)-3,5-dicarbmethoxy 1,4-dihydro
pyridine (XXk)
A mixture of 1-N-phenyl-3-(p-bromol phenyl)pyrazol-4-carboxaldehyde
(3.27gm, 0.01M), methyl aceto acetate  (2.32ml, 0.02M) and p-toludine (1.07gm,
0.01M) in ethanol (30 ml) was heated under reflux condition for six hrs. The con-
tent was poured into  ice cold water.  The seperated solid was filtered and crystal-
lized from DMF:dioxan (2:1). Yield : 57%, M.P. : 229°C, Rf1
 : 0.51, Rf2
 : 0.63
(Required :C, 64.70%; H, 4.90%; N, 6.86% for C33H 30N3O4Br, Found :
C, 64.64%; H, 4.85%; N, 6.81%)
.
Similarly, other compounds (XXa-l) were synthesized. The physical data
are recorded in Table No. 20.
(C) Antimicrobial activity of 1-N-aryl -  2 ,6-dimethyl-4- (1’-N-phenyl-3’-(p-
bromophenyl)-pyrazol-4’-yl)-3,5-dicarbmethoxy 1,4-dihydro pyridines
(XXa-l).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 43. The MIC values of test solution are recorded in Table No.
20a,20b,20c.
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